{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:01:05Z","timestamp":1791900065111,"version":"4.3.4"},"reference-count":298,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08102-4","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:06:11Z","timestamp":1776161171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peripheral immunochemical considerations in Parkinson disease: sources, targets and crosstalk mechanisms"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0235-6847","authenticated-orcid":false,"given":"Alessandra","family":"Castegna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Laera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergianni","family":"Moda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Miglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Cianciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Martina","family":"Filannino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Porro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Allan","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Panaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"6","key":"8102_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020, Feb, 11;323(6):548. https:\/\/doi.org\/10.1001\/jama.2019.22360.","journal-title":"JAMA"},{"issue":"7","key":"8102_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/35081564","volume":"2","author":"M Goedert","year":"2001","unstructured":"Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001, Jul;2(7):492\u2013501. https:\/\/doi.org\/10.1038\/35081564.","journal-title":"Nat. Rev. Neurosci"},{"issue":"4","key":"8102_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008, Apr, 1;79(4):368\u201376. https:\/\/doi.org\/10.1136\/jnnp.2007.131045.","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"8102_CR4","doi-asserted-by":"publisher","unstructured":"Pfeiffer RF. Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2016, Jan;22:S119\u201322. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.004.","DOI":"10.1016\/j.parkreldis.2015.09.004"},{"issue":"13","key":"8102_CR5","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.3390\/ijms25137183","volume":"25","author":"M Muleiro Alvarez","year":"2024","unstructured":"Muleiro Alvarez M, Cano-Herrera G, Osorio Mart\u00ednez, Vega Gonzales-Portillo J, Monroy GR, Murguiondo P\u00e9rez, et al. A comprehensive approach to Parkinson\u2019s disease: addressing its molecular, clinical, and therapeutic aspects. IJMS. 2024, Jun, 29;25(13):7183. https:\/\/doi.org\/10.3390\/ijms25137183.","journal-title":"IJMS"},{"issue":"9","key":"8102_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/mds.25111","volume":"27","author":"SH Appel","year":"2012","unstructured":"Appel SH. Inflammation in Parkinson\u2019s disease: cause or consequence? Mov Disord. 2012, Aug;27(9):1075\u201377. https:\/\/doi.org\/10.1002\/mds.25111.","journal-title":"Mov Disord"},{"key":"8102_CR7","doi-asserted-by":"publisher","first-page":"855776","DOI":"10.3389\/fnagi.2022.855776","volume":"14","author":"M Fathi","year":"2022","unstructured":"Fathi M, Vakili K, Yaghoobpoor S, Qadirifard MS, Kosari M, Naghsh N, et al. Pre-clinical studies identifying molecular pathways of neuroinflammation in Parkinson\u2019s disease: a systematic review. Front Aging Neurosci. 2022, Jul, 4;14:855776. https:\/\/doi.org\/10.3389\/fnagi.2022.855776.","journal-title":"Front Aging Neurosci"},{"key":"8102_CR8","doi-asserted-by":"publisher","unstructured":"Harms AS, Yang YT, Tansey MG. Central and peripheral innate and adaptive immunity in Parkinson\u2019s disease. Sci Transl Med. 2023, Nov, 8;15(721):eadk 3225. https:\/\/doi.org\/10.1126\/scitranslmed.adk3225.","DOI":"10.1126\/scitranslmed.adk3225"},{"key":"8102_CR9","doi-asserted-by":"crossref","unstructured":"Schonhoff AM, Williams GP, Wallen ZD, Standaert DG, Harms AS. Innate and adaptive immune responses in Parkinson\u2019s disease. In: Progress in brain research [internet]. Elsevier; 2020. p. 169\u2013216. [cited 2025 Sep 12]. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612319302031.","DOI":"10.1016\/bs.pbr.2019.10.006"},{"issue":"7","key":"8102_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/acn3.580","volume":"5","author":"BA Racette","year":"2018","unstructured":"Racette BA, Gross A, Vouri SM, Camacho-Soto A, Willis AW, Searles Nielsen S. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol. 2018, Jul;5(7):870\u201375. https:\/\/doi.org\/10.1002\/acn3.580.","journal-title":"Ann. Clin. Transl. Neurol"},{"key":"8102_CR11","doi-asserted-by":"publisher","first-page":"1529197","DOI":"10.3389\/fnagi.2025.1529197","volume":"17","author":"J Zhao","year":"2025","unstructured":"Zhao J, Wu Z, Cai F, Yu X, Song Z. Higher systemic immune-inflammation index is associated with increased risk of Parkinson\u2019s disease in adults: a nationwide population-based study. Front Aging Neurosci. 2025, Feb, 7;17:1529197. https:\/\/doi.org\/10.3389\/fnagi.2025.1529197.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"8102_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/mds.29363","volume":"38","author":"TA Yacoubian","year":"2023","unstructured":"Yacoubian TA, Fang YHD, Gerstenecker A, Amara A, Stover N, Ruffrage L, et al. Brain and systemic inflammation in de novo Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2023, May;38(5):743\u201354. https:\/\/doi.org\/10.1002\/mds.29363.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"8102_CR13","doi-asserted-by":"crossref","unstructured":"Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson\u2019s disease. Front neuroanat [Internet]. 2015 Jul 8. [cited 2025 Sep 12];9. Available from: http:\/\/journal.frontiersin.org\/Article\/10.3389\/fnana.2015.00091\/abstract.","DOI":"10.3389\/fnana.2015.00091"},{"key":"8102_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-981-13-9913-8_13","volume-title":"Neuroglia in Neurodegenerative Diseases [Internet]","author":"MS Ho","year":"2019","unstructured":"Ho MS. Microglia in Parkinson\u2019s disease. In: Verkhratsky A, Ho MS, Zorec R, Parpura V, editors. Neuroglia in Neurodegenerative Diseases [Internet]. Singapore: Springer Singapore; 2019. [cited 2025 Sep 12]. p. 335\u201353. (Advances in Experimental Medicine and Biology; vol. 1175). Available from: https:\/\/doi.org\/10.1007\/978-981-13-9913-8_13."},{"issue":"2","key":"8102_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0304-3940(94)90508-8","volume":"180","author":"M Mogi","year":"1994","unstructured":"Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, et al. Interleukin-1\u03b2, interleukin-6, epidermal growth factor and transforming growth factor-\u03b1 are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994, Oct;180(2):147\u201350. https:\/\/doi.org\/10.1016\/0304-3940(94)90508-8.","journal-title":"Neurosci Lett"},{"issue":"1","key":"8102_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13041-017-0340-9","volume":"10","author":"L Puspita","year":"2017","unstructured":"Puspita L, Chung SY, Shim J-W. Oxidative stress and cellular pathologies in Parkinson\u2019s disease. Mol Brain. 2017, Dec;10(1):53. https:\/\/doi.org\/10.1186\/s13041-017-0340-9.","journal-title":"Mol Brain"},{"issue":"7638","key":"8102_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017, Jan;541(7638):481\u201387. https:\/\/doi.org\/10.1038\/nature21029.","journal-title":"Nature"},{"issue":"10","key":"8102_CR18","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1093\/brain\/awae177","volume":"147","author":"C Roodveldt","year":"2024","unstructured":"Roodveldt C, Bernardino L, Oztop-Cakmak O, Dragic M, Fladmark KE, Ertan S, et al. The immune system in Parkinson\u2019s disease: what we know so far. Brain. 2024, Oct, 3;147(10):3306\u201324. https:\/\/doi.org\/10.1093\/brain\/awae177.","journal-title":"Brain"},{"issue":"11","key":"8102_CR19","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"XY Qin","year":"2016","unstructured":"Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 2016, Nov, 1;73(11):1316\u201324. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2742.","journal-title":"JAMA Neurol"},{"issue":"1","key":"8102_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbi.2008.07.003","volume":"23","author":"M Reale","year":"2009","unstructured":"Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, et al. Peripheral cytokines profile in Parkinson\u2019s disease. Brain Behav Immun. 2009, Jan;23(1):55\u201363. https:\/\/doi.org\/10.1016\/j.bbi.2008.07.003.","journal-title":"Brain Behav Immun"},{"issue":"3","key":"8102_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1600-0404.1994.tb02699.x","volume":"90","author":"U Fiszer","year":"2009","unstructured":"Fiszer U, Mix E, Fredrikson S, Kostulas V, Link H. Parkinson\u2019s disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurologica Scandinavica. 2009, Jan, 29;90(3):160\u201366. https:\/\/doi.org\/10.1111\/j.1600-0404.1994.tb02699.x.","journal-title":"Acta Neurologica Scandinavica"},{"issue":"5","key":"8102_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00401-014-1345-4","volume":"128","author":"V Grozdanov","year":"2014","unstructured":"Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, et al. Inflammatory dysregulation of blood monocytes in Parkinson\u2019s disease patients. Acta Neuropathol (Berl). 2014, Nov;128(5):651\u201363. https:\/\/doi.org\/10.1007\/s00401-014-1345-4.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"1","key":"8102_CR23","doi-asserted-by":"publisher","first-page":"10757","DOI":"10.1038\/s41598-018-28986-7","volume":"8","author":"JCM Schlachetzki","year":"2018","unstructured":"Schlachetzki JCM, Prots I, Tao J, Chun HB, Saijo K, Gosselin D, et al. A monocyte gene expression signature in the early clinical course of Parkinson\u2019s disease. Sci Rep. 2018, Jul, 17;8(1):10757. https:\/\/doi.org\/10.1038\/s41598-018-28986-7.","journal-title":"Sci Rep"},{"issue":"12","key":"8102_CR24","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1007\/s00415-022-11258-w","volume":"269","author":"Y Su","year":"2022","unstructured":"Su Y, Shi C, Wang T, Liu C, Yang J, Zhang S, et al. Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson\u2019s disease. J Neurol. 2022, Dec;269(12):6386\u201394. https:\/\/doi.org\/10.1007\/s00415-022-11258-w.","journal-title":"J Neurol"},{"issue":"6183","key":"8102_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/science.1249547","volume":"344","author":"T Raj","year":"2014","unstructured":"Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014, May, 2;344(6183):519\u201323. https:\/\/doi.org\/10.1126\/science.1249547.","journal-title":"Science"},{"issue":"2","key":"8102_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1042\/BST20201091","volume":"51","author":"S Strader","year":"2023","unstructured":"Strader S, West AB. The interplay between monocytes, \u03b1-synuclein and LRRK2 in Parkinson\u2019s disease. Biochem Soc Trans. 2023, Apr, 26;51(2):747\u201358. https:\/\/doi.org\/10.1042\/BST20201091.","journal-title":"Biochem Soc Trans"},{"issue":"9","key":"8102_CR27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s43587-021-00110-x","volume":"1","author":"E Navarro","year":"2021","unstructured":"Navarro E, Udine E, Lopes KDP, Parks M, Riboldi G, Schilder BM, et al. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson\u2019s disease myeloid cells. Nat Aging. 2021, Sep, 14;1(9):850\u201363. https:\/\/doi.org\/10.1038\/s43587-021-00110-x.","journal-title":"Nat Aging"},{"key":"8102_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.expneurol.2017.11.010","volume":"300","author":"AS Harms","year":"2018","unstructured":"Harms AS, Thome AD, Yan Z, Schonhoff AM, Williams GP, Li X, et al. Peripheral monocyte entry is required for alpha-synuclein induced inflammation and neurodegeneration in a model of Parkinson disease. Exp Neurol. 2018, Feb;300:179\u201387. https:\/\/doi.org\/10.1016\/j.expneurol.2017.11.010.","journal-title":"Exp Neurol"},{"issue":"23","key":"8102_CR29","doi-asserted-by":"publisher","first-page":"9592","DOI":"10.1523\/JNEUROSCI.5610-12.2013","volume":"33","author":"AS Harms","year":"2013","unstructured":"Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, et al. MHCII is required for \u03b1-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci. 2013, Jun, 5;33(23):9592\u2013600. https:\/\/doi.org\/10.1523\/JNEUROSCI.5610-12.2013.","journal-title":"J Neurosci"},{"issue":"6","key":"8102_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000107702","volume":"4","author":"S Papapetropoulos","year":"2007","unstructured":"Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E. A Prospective study of familial versus sporadic Parkinson\u2019s disease. Neurodegener Dis. 2007;4(6):424\u201327. https:\/\/doi.org\/10.1159\/000107702.","journal-title":"Neurodegener Dis"},{"issue":"10","key":"8102_CR31","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/ijms18102043","volume":"18","author":"B Huang","year":"2017","unstructured":"Huang B, Liu J, Ju C, Yang D, Chen G, Xu S, et al. Licochalcone a prevents the loss of dopaminergic neurons by inhibiting microglial activation in Lipopolysaccharide (LPS)-induced Parkinson\u2019s disease models. IJMS. 2017, Sep, 22;18(10):2043. https:\/\/doi.org\/10.3390\/ijms18102043.","journal-title":"IJMS"},{"issue":"7","key":"8102_CR32","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"M Pajares","year":"2020","unstructured":"Pajares M, Rojo A, Manda G, Bosc\u00e1 L, Cuadrado A. Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells. 2020, Jul, 14;9(7):1687. https:\/\/doi.org\/10.3390\/cells9071687.","journal-title":"Cells"},{"issue":"9","key":"8102_CR33","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/mds.27115","volume":"32","author":"JA Obeso","year":"2017","unstructured":"Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, et al. Past, present, and future of Parkinson\u2019s disease: a special essay on the 200th anniversary of the Shaking Palsy. Mov Disord. 2017, Sep;32(9):1264\u2013310. https:\/\/doi.org\/10.1002\/mds.27115.","journal-title":"Mov Disord"},{"key":"8102_CR34","doi-asserted-by":"publisher","unstructured":"Koshimori Y, Ko JH, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF, et al. Imaging striatal microglial activation in patients with Parkinson\u2019s disease. Tansey, MG, editor. PLoS One. 2015, Sep, 18;10(9):e0138721. https:\/\/doi.org\/10.1371\/journal.pone.0138721.","DOI":"10.1371\/journal.pone.0138721"},{"key":"8102_CR35","doi-asserted-by":"crossref","unstructured":"Roussakis AA, Piccini P. Molecular imaging of neuroinflammation in idiopathic Parkinson\u2019s disease. International review of neurobiology [Internet]. Elsevier; 2018 [cited 2025 Sep 11]. p. 347\u201363. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S007477421830076X.","DOI":"10.1016\/bs.irn.2018.08.009"},{"key":"8102_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pneurobio.2016.08.002","volume":"155","author":"ME De Stefano","year":"2017","unstructured":"De Stefano ME, Herrero MT. The multifaceted role of metalloproteinases in physiological and pathological conditions in embryonic and adult brains. Prog Neurobiol. 2017, Aug;155:36\u201356. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.08.002.","journal-title":"Prog Neurobiol"},{"issue":"2","key":"8102_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/138161212799040574","volume":"18","author":"M Antonietta Panaro","year":"2012","unstructured":"Antonietta Panaro M, Cianciulli A. Current Opinions and Perspectives on the role of immune system in the pathogenesis of Parkinson\u2019s disease. CPD. 2012, Jan, 1;18(2):200\u201308. https:\/\/doi.org\/10.2174\/138161212799040574.","journal-title":"CPD"},{"issue":"11","key":"8102_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.31083\/j.jin2311203","volume":"23","author":"O Harackiewicz","year":"2024","unstructured":"Harackiewicz O, Grembecka B. The role of microglia and astrocytes in the pathomechanism of neuroinflammation in Parkinson\u2019s disease\u2014focus on alpha-synuclein. J Integr Neurosci. 2024, Nov, 15;23(11):203. https:\/\/doi.org\/10.31083\/j.jin2311203.","journal-title":"J. Integr. Neurosci"},{"issue":"8","key":"8102_CR39","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","volume":"8","author":"L Maroteaux","year":"1988","unstructured":"Maroteaux L, Campanelli J, Scheller R. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988, Aug, 1;8(8):2804\u201315. https:\/\/doi.org\/10.1523\/JNEUROSCI.08-08-02804.1988.","journal-title":"J Neurosci"},{"issue":"1","key":"8102_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-5793(94)00395-5","volume":"345","author":"R Jakes","year":"1994","unstructured":"Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, May, 23;345(1):27\u201332. https:\/\/doi.org\/10.1016\/0014-5793(94)00395-5.","journal-title":"FEBS Lett"},{"issue":"8","key":"8102_CR41","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1523\/JNEUROSCI.22-08-03090.2002","volume":"22","author":"RG Perez","year":"2002","unstructured":"Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for \u03b1-synuclein in the regulation of dopamine biosynthesis. J Neurosci. 2002, Apr, 15;22(8):3090\u201399. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-08-03090.2002.","journal-title":"J Neurosci"},{"issue":"1","key":"8102_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ame2.12001","volume":"1","author":"L Yan","year":"2018","unstructured":"Yan L. Redox imbalance stress in diabetes mellitus: role of the polyol pathway. Anim Model Exp Med. 2018, Mar;1(1):7\u201313. https:\/\/doi.org\/10.1002\/ame2.12001.","journal-title":"Anim Model Exp Med"},{"issue":"5999","key":"8102_CR43","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burr\u00e9","year":"2010","unstructured":"Burr\u00e9 J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, S\u00fcdhof TC. \u03b1-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010, Sep, 24;329(5999):1663\u201367. https:\/\/doi.org\/10.1126\/science.1195227.","journal-title":"Science"},{"issue":"1","key":"8102_CR44","doi-asserted-by":"publisher","first-page":"10919","DOI":"10.1038\/s41598-019-47227-z","volume":"9","author":"AJ Schaser","year":"2019","unstructured":"Schaser AJ, Osterberg VR, Dent SE, Stackhouse TL, Wakeham CM, Boutros SW, et al. Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders. Sci Rep. 2019, Jul, 29;9(1):10919. https:\/\/doi.org\/10.1038\/s41598-019-47227-z.","journal-title":"Sci Rep"},{"issue":"5321","key":"8102_CR45","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997, Jun, 27;276(5321):2045\u201347. https:\/\/doi.org\/10.1126\/science.276.5321.2045.","journal-title":"Science"},{"issue":"6645","key":"8102_CR46","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. \u03b1-synuclein in Lewy bodies. Nature. 1997, Aug, 28;388(6645):839\u201340. https:\/\/doi.org\/10.1038\/42166.","journal-title":"Nature"},{"key":"8102_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi JC, Hirth F. Mechanisms of \u03b1-synuclein induced Synaptopathy in Parkinson\u2019s disease. Front Neurosci. 2018, Feb, 19;12:80. https:\/\/doi.org\/10.3389\/fnins.2018.00080.","journal-title":"Front. Neurosci"},{"issue":"3","key":"8102_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00401-021-02324-0","volume":"142","author":"S Dutta","year":"2021","unstructured":"Dutta S, Hornung S, Kruayatidee A, Maina KN, Del Rosario I, Paul KC, et al. \u03b1-synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson\u2019s disease from multiple system atrophy. Acta Neuropathol (Berl). 2021, Sep;142(3):495\u2013511. https:\/\/doi.org\/10.1007\/s00401-021-02324-0.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"34","key":"8102_CR49","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","volume":"27","author":"KM Danzer","year":"2007","unstructured":"Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of \u03b1-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007, Aug, 22;27(34):9220\u201332. https:\/\/doi.org\/10.1523\/JNEUROSCI.2617-07.2007.","journal-title":"J Neurosci"},{"issue":"2","key":"8102_CR50","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. \u03b1-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002, Feb;4(2):160\u201364. https:\/\/doi.org\/10.1038\/ncb748.","journal-title":"Nat Cell Biol"},{"issue":"40","key":"8102_CR51","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson JP, Walker DE, Goldstein JM, De Laat R, Banducci K, Caccavello RJ, et al. Phosphorylation of ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic lewy body disease. J Biol Chem. 2006, Oct;281(40):29739\u201352. https:\/\/doi.org\/10.1074\/jbc.M600933200.","journal-title":"J Biol Chem"},{"issue":"11","key":"8102_CR52","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/cn200074d","volume":"2","author":"Y Lu","year":"2011","unstructured":"Lu Y, Prudent M, Fauvet B, Lashuel HA, Girault HH. Phosphorylation of \u03b1-synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of \u03b1-synuclein in the pathogenesis of Parkinson\u2019s disease and related disorders. ACS Chem. Neurosci. 2011, Nov, 16;2(11):667\u201375. https:\/\/doi.org\/10.1021\/cn200074d.","journal-title":"ACS Chem. Neurosci"},{"issue":"1","key":"8102_CR53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00441-017-2775-9","volume":"373","author":"V Grozdanov","year":"2018","unstructured":"Grozdanov V, Danzer KM. Release and uptake of pathologic alpha-synuclein. Cell Tissue Res. 2018, Jul;373(1):175\u201382. https:\/\/doi.org\/10.1007\/s00441-017-2775-9.","journal-title":"Cell Tissue Res"},{"key":"8102_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbi.2019.06.042","volume":"81","author":"A Kouli","year":"2019","unstructured":"Kouli A, Horne CB, Williams-Gray CH. Toll-like receptors and their therapeutic potential in Parkinson\u2019s disease and \u03b1-synucleinopathies. Brain Behav Immun. 2019, Oct;81:41\u201351. https:\/\/doi.org\/10.1016\/j.bbi.2019.06.042.","journal-title":"Brain Behav Immun"},{"issue":"3","key":"8102_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/glia.20235","volume":"52","author":"X Zhang","year":"2005","unstructured":"Zhang X, Haaf M, Todorich B, Grosstephan E, Schieremberg H, Surguladze N, et al. Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia. 2005, Nov, 15;52(3):199\u2013208. https:\/\/doi.org\/10.1002\/glia.20235.","journal-title":"Glia"},{"issue":"1","key":"8102_CR56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11481-012-9401-0","volume":"8","author":"D B\u00e9raud","year":"2013","unstructured":"B\u00e9raud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, et al. Microglial activation and antioxidant responses induced by the Parkinson\u2019s disease protein \u03b1-synuclein. J Neuroimmune Pharmacol Off J Soc Neuroimmune Pharmacol. 2013, Mar;8(1):94\u2013117. https:\/\/doi.org\/10.1007\/s11481-012-9401-0.","journal-title":"J Neuroimmune Pharmacol Off J Soc Neuroimmune Pharmacol"},{"issue":"2","key":"8102_CR57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/glia.1106","volume":"36","author":"F Aloisi","year":"2001","unstructured":"Aloisi F. Immune function of microglia. Glia. 2001, Nov;36(2):165\u201379. https:\/\/doi.org\/10.1002\/glia.1106.","journal-title":"Glia"},{"issue":"3","key":"8102_CR58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0165-0173(94)00015-H","volume":"20","author":"J Gehrmann","year":"1995","unstructured":"Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immuneffector cell of the brain. Brain Res Rev. 1995, Mar;20(3):269\u201387. https:\/\/doi.org\/10.1016\/0165-0173(94)00015-H.","journal-title":"Brain Res Rev"},{"issue":"1","key":"8102_CR59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1326-4-47","volume":"4","author":"TC Frank-Cannon","year":"2009","unstructured":"Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener. 2009, Dec;4(1):47. https:\/\/doi.org\/10.1186\/1750-1326-4-47.","journal-title":"Mol Neurodegener"},{"key":"8102_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pneurobio.2015.05.003","volume":"131","author":"R Franco","year":"2015","unstructured":"Franco R, Fern\u00e1ndez-Su\u00e1rez D. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol. 2015, Aug;131:65\u201386. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.05.003.","journal-title":"Prog Neurobiol"},{"issue":"13","key":"8102_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.03-0098fje","volume":"17","author":"OMA El-Agnaf","year":"2003","unstructured":"El-Agnaf OMA, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, et al. \u03b1-synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma. The FASEB J. 2003, Oct;17(13):1\u201316. https:\/\/doi.org\/10.1096\/fj.03-0098fje.","journal-title":"The FASEB J"},{"key":"8102_CR62","doi-asserted-by":"publisher","unstructured":"Marques O, Outeiro TF. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 2012, Jul, 19;3(7):e350\u2013350. https:\/\/doi.org\/10.1038\/cddis.2012.94.","DOI":"10.1038\/cddis.2012.94"},{"key":"8102_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainres.2011.11.012","volume":"1432","author":"K Nakamoto","year":"2012","unstructured":"Nakamoto K, Nishinaka T, Matsumoto K, Kasuya F, Mankura M, Koyama Y, et al. Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res. 2012, Jan;1432:74\u201383. https:\/\/doi.org\/10.1016\/j.brainres.2011.11.012.","journal-title":"Brain Res"},{"key":"8102_CR64","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.neuropharm.2015.05.013","volume":"113","author":"MZ Khan","year":"2017","unstructured":"Khan MZ, He L. The role of polyunsaturated fatty acids and GPR40 receptor in brain. Neuropharmacology. 2017, Feb;113:639\u201351. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.05.013.","journal-title":"Neuropharmacology"},{"issue":"1","key":"8102_CR65","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/1028415X.2020.1735143","volume":"25","author":"P Li","year":"2022","unstructured":"Li P, Song C. Potential treatment of Parkinson\u2019s disease with omega-3 polyunsaturated fatty acids. Nutritional Neurosci. 2022, Jan;25(1):180\u201391. https:\/\/doi.org\/10.1080\/1028415X.2020.1735143.","journal-title":"Nutritional Neurosci"},{"key":"8102_CR66","doi-asserted-by":"publisher","first-page":"107432","DOI":"10.1016\/j.phrs.2024.107432","volume":"209","author":"TY Ha","year":"2024","unstructured":"Ha TY, Kim JB, Kim Y, Park SM, Chang KA. GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson\u2019s disease animal models. Pharmacological Res. 2024, Nov;209:107432. https:\/\/doi.org\/10.1016\/j.phrs.2024.107432.","journal-title":"Pharmacological Res"},{"issue":"1","key":"8102_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00702-020-02271-2","volume":"128","author":"A Martin-Bastida","year":"2021","unstructured":"Martin-Bastida A, Tilley BS, Bansal S, Gentleman SM, Dexter DT, Ward RJ. Iron and inflammation: in vivo and post-mortem studies in Parkinson\u2019s disease. J Neural Transm Vienna Austria 1996. 2021, Jan;128(1):15\u201325. https:\/\/doi.org\/10.1007\/s00702-020-02271-2.","journal-title":"J Neural Transm Vienna Austria"},{"issue":"1","key":"8102_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Sig Transduct Target Ther. 2024, Oct, 14;9(1):271. https:\/\/doi.org\/10.1038\/s41392-024-01969-z.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"8102_CR69","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep. 2017, May, 3;7(1):1398. https:\/\/doi.org\/10.1038\/s41598-017-01402-2.","journal-title":"Sci Rep"},{"key":"8102_CR70","doi-asserted-by":"publisher","first-page":"105273","DOI":"10.1016\/j.nbd.2021.105273","volume":"151","author":"A Marquez","year":"2021","unstructured":"Marquez A, Guernsey LS, Frizzi KE, Cundiff M, Constantino I, Muttalib N, et al. Tau associated peripheral and central neurodegeneration: identification of an early imaging marker for tauopathy. Neurobiol Disease. 2021, Apr;151:105273. https:\/\/doi.org\/10.1016\/j.nbd.2021.105273.","journal-title":"Neurobiol Disease"},{"issue":"4","key":"8102_CR71","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/1073858420943180","volume":"27","author":"H Zheng","year":"2021","unstructured":"Zheng H, Shi C, Luo H, Fan L, Yang Z, Hu X, et al. \u03b1-synuclein in Parkinson\u2019s disease: does a prion-like mechanism of propagation from periphery to the brain play a role? The Neuroscientist. 2021, Aug;27(4):367\u201387. https:\/\/doi.org\/10.1177\/1073858420943180.","journal-title":"The Neuroscientist"},{"key":"8102_CR72","doi-asserted-by":"publisher","first-page":"114887","DOI":"10.1016\/j.expneurol.2024.114887","volume":"379","author":"GT Sagredo","year":"2024","unstructured":"Sagredo GT, Tanglay O, Shahdadpuri S, Fu Y, Halliday GM. \u237a-synuclein levels in Parkinson\u2019s disease \u2013 cell types and forms that contribute to pathogenesis. Exp Neurol. 2024, Sep;379:114887. https:\/\/doi.org\/10.1016\/j.expneurol.2024.114887.","journal-title":"Exp Neurol"},{"key":"8102_CR73","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fneur.2019.01388","volume":"10","author":"CW Chang","year":"2020","unstructured":"Chang CW, Yang SY, Yang CC, Chang CW, Wu YR. Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson\u2019s disease. Front Neurol. 2020, Jan, 21;10:1388. https:\/\/doi.org\/10.3389\/fneur.2019.01388.","journal-title":"Front Neurol"},{"key":"8102_CR74","doi-asserted-by":"publisher","first-page":"562692","DOI":"10.3389\/fcell.2020.562692","volume":"8","author":"V Grozdanov","year":"2020","unstructured":"Grozdanov V, Danzer KM. Intracellular alpha-synuclein and immune cell function. Front. Cell Dev. Biol. 2020, Oct, 15;8:562692. https:\/\/doi.org\/10.3389\/fcell.2020.562692.","journal-title":"Front. Cell Dev. Biol"},{"issue":"8","key":"8102_CR75","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/biom13081263","volume":"13","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2023","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Alonso-Navarro H, Garc\u00eda-Mart\u00edn E, Santos-Garc\u00eda D, Mart\u00ednez-Valbuena I, Ag\u00fandez JAG. Alpha-synuclein in peripheral tissues as a possible marker for Neurological diseases and other medical conditions. Biomolecules. 2023, Aug, 18;13(8):1263. https:\/\/doi.org\/10.3390\/biom13081263.","journal-title":"Biomolecules"},{"issue":"6109","key":"8102_CR76","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ, et al. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012, Nov, 16;338(6109):949\u201353. https:\/\/doi.org\/10.1126\/science.1227157.","journal-title":"Science"},{"issue":"3","key":"8102_CR77","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens A, Dehay B, Bov\u00e9 J, Carballo-Carbajal I, Dovero S, P\u00e9rez-Villalba A, et al. Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014, Mar;75(3):351\u201362. https:\/\/doi.org\/10.1002\/ana.24066.","journal-title":"Ann Neurol"},{"issue":"1","key":"8102_CR78","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40478-017-0413-0","volume":"5","author":"A Shimozawa","year":"2017","unstructured":"Shimozawa A, Ono M, Takahara D, Tarutani A, Imura S, Masuda-Suzukake M, et al. Propagation of pathological \u03b1-synuclein in marmoset brain. Acta Neuropathol Commun. 2017, Dec;5(1):12. https:\/\/doi.org\/10.1186\/s40478-017-0413-0.","journal-title":"Acta Neuropathol Commun"},{"key":"8102_CR79","doi-asserted-by":"publisher","first-page":"114574","DOI":"10.1016\/j.bbr.2023.114574","volume":"452","author":"V Schmitt","year":"2023","unstructured":"Schmitt V, Masanetz RK, Weidenfeller M, Ebbinghaus LS, S\u00fc\u00df P, Rosshart SP, et al. Gut-to-brain spreading of pathology in synucleinopathies: a focus on molecular signalling mediators. Behavioural Brain Res. 2023, Aug;452:114574. https:\/\/doi.org\/10.1016\/j.bbr.2023.114574.","journal-title":"Behavioural Brain Res"},{"issue":"1","key":"8102_CR80","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-018-0066-0","volume":"4","author":"L Anselmi","year":"2018","unstructured":"Anselmi L, Bove C, Coleman FH, Le K, Subramanian MP, Venkiteswaran K, et al. Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat. Npj Parkinson\u2019s Disease. 2018, Sep, 27;4(1):30. https:\/\/doi.org\/10.1038\/s41531-018-0066-0.","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"8102_CR81","doi-asserted-by":"publisher","unstructured":"Ayers JI, Brooks MM, Rutherford NJ, Howard JK, Sorrentino ZA, Riffe CJ, et al. Robust central nervous system pathology in transgenic mice following peripheral injection of \u03b1-synuclein fibrils. Caughey, B, editor. J Virol. 2017 Jan 15; 91(2):e02095\u201316. https:\/\/doi.org\/10.1128\/JVI.02095-16.","DOI":"10.1128\/JVI.02095-16"},{"key":"8102_CR82","doi-asserted-by":"publisher","first-page":"105557","DOI":"10.1016\/j.nbd.2021.105557","volume":"161","author":"P Borghammer","year":"2021","unstructured":"Borghammer P, Horsager J, Andersen K, Van Den Berge N, Raunio A, Murayama S, et al. Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiol Dis. 2021, Dec;161:105557. https:\/\/doi.org\/10.1016\/j.nbd.2021.105557.","journal-title":"Neurobiol Disease"},{"key":"8102_CR83","doi-asserted-by":"publisher","unstructured":"Chandra R, Hiniker A, Kuo YM, Nussbaum RL, Liddle RA. \u03b1-synuclein in gut endocrine cells and its implications for Parkinson\u2019s disease. JCI Insight. 2017, Jun, 15;2(12):e92295. https:\/\/doi.org\/10.1172\/jci.insight.92295.","DOI":"10.1172\/jci.insight.92295"},{"issue":"11","key":"8102_CR84","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1111\/ene.15607","volume":"30","author":"G Bellini","year":"2023","unstructured":"Bellini G, Benvenuti L, Ippolito C, Frosini D, Segnani C, Rettura F, et al. Intestinal histomorphological and molecular alterations in patients with Parkinson\u2019s disease. Euro J Neurol. 2023, Nov;30(11):3440\u201350. https:\/\/doi.org\/10.1111\/ene.15607.","journal-title":"Euro J Neurol"},{"issue":"1","key":"8102_CR85","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S2468-1253(22)00241-2","volume":"8","author":"C Pellegrini","year":"2023","unstructured":"Pellegrini C, Fornai M, D\u2019Antongiovanni V, Antonioli L, Bernardini N, Derkinderen P. The intestinal barrier in disorders of the central nervous system. The Lancet Gastroenterol Hepatol. 2023, Jan;8(1):66\u201380. https:\/\/doi.org\/10.1016\/S2468-1253(22)00241-2.","journal-title":"The Lancet Gastroenterol Hepatol"},{"issue":"1","key":"8102_CR86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-019-0146-z","volume":"8","author":"L Rota","year":"2019","unstructured":"Rota L, Pellegrini C, Benvenuti L, Antonioli L, Fornai M, Blandizzi C, et al. Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. Transl Neurodegener. 2019, Dec;8(1):5. https:\/\/doi.org\/10.1186\/s40035-019-0146-z.","journal-title":"Transl Neurodegener"},{"issue":"6","key":"8102_CR87","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","volume":"119","author":"TG Beach","year":"2010","unstructured":"Beach TG, Adler CH, Sue LI, Vedders LI, Lue L, White Iii L, et al. Multi-organ distribution of phosphorylated \u03b1-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (Berl). 2010, Jun;119(6):689\u2013702. https:\/\/doi.org\/10.1007\/s00401-010-0664-3.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"8","key":"8102_CR88","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/mds.25776","volume":"29","author":"E Gelpi","year":"2014","unstructured":"Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord. 2014, Jul;29(8):1010\u201318. https:\/\/doi.org\/10.1002\/mds.25776.","journal-title":"Mov Disord"},{"issue":"3","key":"8102_CR89","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00401-018-1856-5","volume":"136","author":"C Pellegrini","year":"2018","unstructured":"Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? Acta Neuropathol (Berl). 2018, Sep;136(3):345\u201361. https:\/\/doi.org\/10.1007\/s00401-018-1856-5.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"6","key":"8102_CR90","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell. 2016, Dec;167(6):1469\u201380.e12. https:\/\/doi.org\/10.1016\/j.cell.2016.11.018.","journal-title":"Cell"},{"issue":"5","key":"8102_CR91","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jnc.14809","volume":"150","author":"M Fayyad","year":"2019","unstructured":"Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, et al. Parkinson\u2019s disease biomarkers based on \u03b1-synuclein. J Neurochem. 2019, Sep;150(5):626\u201336. https:\/\/doi.org\/10.1111\/jnc.14809.","journal-title":"J Neurochem"},{"issue":"1","key":"8102_CR92","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41531-022-00357-0","volume":"8","author":"P Magalh\u00e3es","year":"2022","unstructured":"Magalh\u00e3es P, Lashuel HA. Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson\u2019s disease and other synucleinopathies. Npj Parkinsons Dis. 2022, Jul, 22;8(1):93. https:\/\/doi.org\/10.1038\/s41531-022-00357-0.","journal-title":"Npj Parkinsons Dis"},{"key":"8102_CR93","doi-asserted-by":"publisher","first-page":"569777","DOI":"10.3389\/fnins.2020.569777","volume":"14","author":"R He","year":"2020","unstructured":"He R, Zhao Y, He Y, Zhou Y, Yang J, Zhou X, et al. Olfactory dysfunction predicts disease progression in Parkinson\u2019s disease: a longitudinal study. Front. Neurosci. 2020, Dec, 14;14:569777. https:\/\/doi.org\/10.3389\/fnins.2020.569777.","journal-title":"Front. Neurosci"},{"issue":"1","key":"8102_CR94","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40035-022-00311-3","volume":"11","author":"M Bongianni","year":"2022","unstructured":"Bongianni M, Catalan M, Perra D, Fontana E, Janes F, Bertolotti C, et al. Olfactory swab sampling optimization for \u03b1-synuclein aggregate detection in patients with Parkinson\u2019s disease. Transl Neurodegener. 2022, Jul, 28;11(1):37. https:\/\/doi.org\/10.1186\/s40035-022-00311-3.","journal-title":"Transl Neurodegener"},{"issue":"4","key":"8102_CR95","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/brain\/awab005","volume":"144","author":"A Stefani","year":"2021","unstructured":"Stefani A, Iranzo A, Holzknecht E, Perra D, Bongianni M, Gaig C, et al. For the SINBAR (sleep Innsbruck Barcelona) group. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain. 2021, May, 7;144(4):1118\u201326. https:\/\/doi.org\/10.1093\/brain\/awab005.","journal-title":"Brain"},{"issue":"1","key":"8102_CR96","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41531-022-00436-2","volume":"8","author":"P Borghammer","year":"2022","unstructured":"Borghammer P, Just MK, Horsager J, Skj\u00e6rb\u00e6k C, Raunio A, Kok EH, et al. A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson\u2019s disease. Npj Parkinsons Dis. 2022, Nov, 30;8(1):166. https:\/\/doi.org\/10.1038\/s41531-022-00436-2.","journal-title":"Npj Parkinsons Dis"},{"issue":"1","key":"8102_CR97","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1212\/CON.0000000000000814","volume":"26","author":"CH Gibbons","year":"2020","unstructured":"Gibbons CH, Wang N, Kim JY, Campagnolo M, Freeman R. Skin Biopsy in evaluation of autonomic disorders. Continuum. 2020, Feb;26(1):200\u201312. https:\/\/doi.org\/10.1212\/CON.0000000000000814.","journal-title":"Continuum"},{"issue":"10","key":"8102_CR98","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1369\/0022155420960250","volume":"68","author":"N Wang","year":"2020","unstructured":"Wang N, Garcia J, Freeman R, Gibbons CH. Phosphorylated alpha-synuclein within cutaneous autonomic nerves of patients with Parkinson\u2019s disease: the implications of sample thickness on results. J Histochem Cytochem. 2020, Oct;68(10):669\u201378. https:\/\/doi.org\/10.1369\/0022155420960250.","journal-title":"J Histochem Cytochem"},{"key":"8102_CR99","doi-asserted-by":"publisher","unstructured":"Donadio V, Wang Z, Incensi A, Rizzo G, Fileccia E, Vacchiano V, et al. In vivo diagnosis of synucleinopathies: a comparative study of skin Biopsy and RT-QuIC. Neurology [Internet]. 2021, May, 18;96(20). Available from: https:\/\/doi.org\/10.1212\/WNL.0000000000011935. 2025 Sep 12.","DOI":"10.1212\/WNL.0000000000011935"},{"key":"8102_CR100","doi-asserted-by":"publisher","unstructured":"Peng W, Schr\u00f6der LF, Song P, Wong YC, Krainc D. Parkin regulates amino acid homeostasis at mitochondria-lysosome (M\/L) contact sites in Parkinson\u2019s disease. Sci Adv. 2023, Jul, 21;9(29):eadh 3347. https:\/\/doi.org\/10.1126\/sciadv.adh3347.","DOI":"10.1126\/sciadv.adh3347"},{"issue":"2","key":"8102_CR101","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003, Mar;24(2):197\u2013211. https:\/\/doi.org\/10.1016\/S0197-4580(02)00065-9.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"8102_CR102","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004, Oct;318(1):121\u201334. https:\/\/doi.org\/10.1007\/s00441-004-0956-9.","journal-title":"Cell Tissue Res"},{"key":"8102_CR103","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.expneurol.2017.03.010","volume":"292","author":"BAS Reyes","year":"2017","unstructured":"Reyes BAS, Carvalho AF, Szot P, Kalamarides DJ, Wang Q, Kirby LG, et al. Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion. Exp Neurol. 2017, Jun;292:179\u201392. https:\/\/doi.org\/10.1016\/j.expneurol.2017.03.010.","journal-title":"Exp Neurol"},{"issue":"6","key":"8102_CR104","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.immuni.2017.06.007","volume":"46","author":"J Herz","year":"2017","unstructured":"Herz J, Filiano AJ, Wiltbank AT, Yogev N, Kipnis J. Myeloid cells in the central nervous system. Immunity. 2017, Jun;46(6):943\u201356. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.007.","journal-title":"Immunity"},{"issue":"3","key":"8102_CR105","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00401-015-1504-2","volume":"131","author":"C Bliederhaeuser","year":"2016","unstructured":"Bliederhaeuser C, Grozdanov V, Speidel A, Zondler L, Ruf WP, Bayer H, et al. Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathol (Berl). 2016, Mar;131(3):379\u201391. https:\/\/doi.org\/10.1007\/s00401-015-1504-2.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"4","key":"8102_CR106","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/(SICI)1097-4547(20000215)59:4<522::AID-JNR7>3.0.CO;2-L","volume":"59","author":"RB Weltzien","year":"2000","unstructured":"Weltzien RB, Pachter JS. Visualization of beta-amyloid peptide (A?) phagocytosis by human mononuclear phagocytes: dependency on A? aggregate size. J. Neurosci. Res. 2000, Feb, 15;59(4):522\u201327. https:\/\/doi.org\/10.1002\/(SICI)1097-4547(20000215)59:4%3C522::AID-JNR7%3E3.0.CO;2-L.","journal-title":"J. Neurosci. Res"},{"issue":"4","key":"8102_CR107","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JPD-130250","volume":"3","author":"GT Kannarkat","year":"2013","unstructured":"Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson\u2019s disease. J Educ Chang Parkinson\u2019s Disease. 2013, Nov, 1;3(4):493\u2013514. https:\/\/doi.org\/10.3233\/JPD-130250.","journal-title":"J Educ Chang Parkinson\u2019s Disease"},{"key":"8102_CR108","doi-asserted-by":"publisher","unstructured":"Gardai SJ, Mao W, Sch\u00fcle B, Babcock M, Schoebel S, Lorenzana C, et al. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson\u2019s disease. PLoS One. 2013;8(8):e71634. https:\/\/doi.org\/10.1371\/journal.pone.0071634.","DOI":"10.1371\/journal.pone.0071634"},{"issue":"3","key":"8102_CR109","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1034\/j.1600-0404.2000.101003159.x","volume":"101","author":"Y Hasegawa","year":"2000","unstructured":"Hasegawa Y, Inagaki T, Sawada M, Suzumura A. Impaired cytokine production by peripheral blood mononuclear cells and monocytes\/macrophages in Parkinson\u2019s disease. Acta Neurologica Scandinavica. 2000, Mar;101(3):159\u201364. https:\/\/doi.org\/10.1034\/j.1600-0404.2000.101003159.x.","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"8102_CR110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-017-0010-8","volume":"3","author":"DA Cook","year":"2017","unstructured":"Cook DA, Kannarkat GT, Cintron AF, Butkovich LM, Fraser KB, Chang J, et al. LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. Npj Parkinson\u2019s Disease. 2017;3(1):11. https:\/\/doi.org\/10.1038\/s41531-017-0010-8.","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"2","key":"8102_CR111","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0022-1759(97)00157-9","volume":"209","author":"J Bernardo","year":"1997","unstructured":"Bernardo J, Billingslea AM, Ortiz MF, Seetoo KF, Macauley J, Simons ER. Adherence-dependent calcium signaling in monocytes: induction of a CD14-high phenotype, stimulus-responsive subpopulation. J Immunol Methods. 1997, Dec;209(2):165\u201375. https:\/\/doi.org\/10.1016\/S0022-1759(97)00157-9.","journal-title":"J Immunol Methods"},{"issue":"11","key":"8102_CR112","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.3390\/ijms22115887","volume":"22","author":"R Han","year":"2021","unstructured":"Han R, Liang J, Zhou B. Glucose metabolic dysfunction in neurodegenerative diseases\u2014New mechanistic insights and the potential of hypoxia as a Prospective therapy targeting metabolic reprogramming. IJMS. 2021, May, 31;22(11):5887. https:\/\/doi.org\/10.3390\/ijms22115887.","journal-title":"IJMS"},{"issue":"1","key":"8102_CR113","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12974-024-03296-0","volume":"21","author":"M Sadeghdoust","year":"2024","unstructured":"Sadeghdoust M, Das A, Kaushik DK. Fueling neurodegeneration: metabolic insights into microglia functions. J Neuroinflammation. 2024, Nov, 17;21(1):300. https:\/\/doi.org\/10.1186\/s12974-024-03296-0.","journal-title":"J Neuroinflammation"},{"issue":"11","key":"8102_CR114","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.27815","volume":"34","author":"SK Nissen","year":"2019","unstructured":"Nissen SK, Shrivastava K, Schulte C, Otzen DE, Goldeck D, Berg D, et al. Alterations in blood monocyte functions in Parkinson\u2019s disease. Mov Disord. 2019, Nov;34(11):1711\u201321. https:\/\/doi.org\/10.1002\/mds.27815.","journal-title":"Mov Disord"},{"key":"8102_CR115","doi-asserted-by":"publisher","first-page":"1571074","DOI":"10.3389\/fimmu.2025.1571074","volume":"16","author":"AD Thome","year":"2025","unstructured":"Thome AD, Wang J, Atassi F, Thonhoff JR, Faridar A, Zhao W, et al. Peripheral monocyte transcriptional signatures of inflammation and oxidative stress in Parkinson\u2019s disease. Front. Immunol. 2025, Jul, 23;16:1571074. https:\/\/doi.org\/10.3389\/fimmu.2025.1571074.","journal-title":"Front. Immunol"},{"issue":"10","key":"8102_CR116","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/mds.104","volume":"33","author":"AM Smith","year":"2018","unstructured":"Smith AM, Depp C, Ryan BJ, Johnston GI, Alegre-Abarrategui J, Evetts S, et al. Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson\u2019s blood cells. Mov Disord. 2018, Oct;33(10):1580\u201390. https:\/\/doi.org\/10.1002\/mds.104.","journal-title":"Mov Disord"},{"key":"8102_CR117","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","volume":"43","author":"A Galbiati","year":"2019","unstructured":"Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L. The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies. Sleep Med Rev. 2019, Feb;43:37\u201346. https:\/\/doi.org\/10.1016\/j.smrv.2018.09.008.","journal-title":"Sleep Med Rev"},{"key":"8102_CR118","doi-asserted-by":"publisher","unstructured":"Uehara I, Kajita M, Tanimura A, Hida S, Onda M, Naito Z, et al. 2-deoxy- d -glucose induces deglycosylation of proinflammatory cytokine receptors and strongly reduces immunological responses in mouse models of inflammation. Pharmacol Res & Perspec. 2022, Apr;10(2):e00940. https:\/\/doi.org\/10.1002\/prp2.940.","DOI":"10.1002\/prp2.940"},{"issue":"3","key":"8102_CR119","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci. 2019, Mar;20(3):148\u201360. https:\/\/doi.org\/10.1038\/s41583-019-0132-6.","journal-title":"Nat. Rev. Neurosci"},{"issue":"22","key":"8102_CR120","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e3181ff9685","volume":"75","author":"H Mortiboys","year":"2010","unstructured":"Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology. 2010, Nov, 30;75(22):2017\u201320. https:\/\/doi.org\/10.1212\/WNL.0b013e3181ff9685.","journal-title":"Neurology"},{"issue":"4","key":"8102_CR121","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tibs.2015.02.003","volume":"40","author":"BJ Ryan","year":"2015","unstructured":"Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson\u2019s: from familial to sporadic disease. Trends Biochemical Sci. 2015, Apr;40(4):200\u201310. https:\/\/doi.org\/10.1016\/j.tibs.2015.02.003.","journal-title":"Trends Biochemical Sci"},{"issue":"16","key":"8102_CR122","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1523\/JNEUROSCI.4441-10.2011","volume":"31","author":"P Seibler","year":"2011","unstructured":"Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci. 2011, Apr, 20;31(16):5970\u201376. https:\/\/doi.org\/10.1523\/JNEUROSCI.4441-10.2011.","journal-title":"J Neurosci"},{"issue":"3","key":"8102_CR123","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.nbd.2010.03.014","volume":"38","author":"JG Greene","year":"2010","unstructured":"Greene JG, Dingledine R, Greenamyre JT. Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents. Neurobiol Disease. 2010, Jun;38(3):476\u201381. https:\/\/doi.org\/10.1016\/j.nbd.2010.03.014.","journal-title":"Neurobiol Disease"},{"issue":"1","key":"8102_CR124","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nbd.2006.01.013","volume":"23","author":"A Prigione","year":"2006","unstructured":"Prigione A, Begni B, Galbussera A, Beretta S, Brighina L, Garofalo R, et al. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson\u2019s disease: negative correlation with levodopa dosage. Neurobiol Disease. 2006, Jul;23(1):36\u201343. https:\/\/doi.org\/10.1016\/j.nbd.2006.01.013.","journal-title":"Neurobiol Disease"},{"key":"8102_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/1452696","volume":"2020","author":"S Rius-P\u00e9rez","year":"2020","unstructured":"Rius-P\u00e9rez S, Torres-Cuevas I, Mill\u00e1n I, Ortega \u00c1L, P\u00e9rez S. PGC-1 \u03b1, inflammation, and oxidative stress: an integrative view in metabolism. Oxidative Med Cellular Longevity. 2020, Mar, 9;2020:1\u201320. https:\/\/doi.org\/10.1155\/2020\/1452696.","journal-title":"Oxidative Med Cellular Longevity"},{"issue":"18","key":"8102_CR126","doi-asserted-by":"publisher","first-page":"14108","DOI":"10.3390\/ijms241814108","volume":"24","author":"J Chu","year":"2023","unstructured":"Chu J, Li J, Sun L, Wei J. The role of cellular defense systems of ferroptosis in Parkinson\u2019s disease and Alzheimer\u2019s disease. IJMS. 2023, Sep, 14;24(18):14108. https:\/\/doi.org\/10.3390\/ijms241814108.","journal-title":"IJMS"},{"issue":"1","key":"8102_CR127","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41467-017-00932-7","volume":"8","author":"P Huppke","year":"2017","unstructured":"Huppke P, Weissbach S, Church JA, Schnur R, Krusen M, Dreha-Kulaczewski S, et al. Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder. Nat Commun. 2017, Oct, 10;8(1):818. https:\/\/doi.org\/10.1038\/s41467-017-00932-7.","journal-title":"Nat Commun"},{"issue":"23","key":"8102_CR128","doi-asserted-by":"publisher","first-page":"12475","DOI":"10.1073\/pnas.220418997","volume":"97","author":"HC Huang","year":"2000","unstructured":"Huang HC, Nguyen T, Pickett CB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc Natl Acad Sci USA. 2000, Nov, 7;97(23):12475\u201380. https:\/\/doi.org\/10.1073\/pnas.220418997.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8102_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8167273","volume":"2016","author":"VT Vachharajani","year":"2016","unstructured":"Vachharajani VT, Liu T, Wang X, Hoth JJ, Yoza BK, McCall CE. Sirtuins link inflammation and metabolism. J Immunol Res. 2016;2016:1\u201310. https:\/\/doi.org\/10.1155\/2016\/8167273.","journal-title":"J Immunol Res"},{"issue":"12","key":"8102_CR130","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.tibs.2010.07.003","volume":"35","author":"E Verdin","year":"2010","unstructured":"Verdin E, Hirschey MD, Finley LWS, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochemical Sci. 2010, Dec;35(12):669\u201375. https:\/\/doi.org\/10.1016\/j.tibs.2010.07.003.","journal-title":"Trends Biochemical Sci"},{"issue":"5","key":"8102_CR131","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/mds.10695","volume":"19","author":"M M\u00fcft\u00fcoglu","year":"2004","unstructured":"M\u00fcft\u00fcoglu M, Elibol B, Dalm\u0131zrak \u00d6, Ercan A, Kulaks\u0131z G, \u00d6g\u00fcs H, et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord. 2004, May;19(5):544\u201348. https:\/\/doi.org\/10.1002\/mds.10695.","journal-title":"Mov Disord"},{"key":"8102_CR132","doi-asserted-by":"crossref","unstructured":"Salemi M, Cosentino F, Lanza G, Cantone M, Salluzzo MG, Giurato G, et al. mRNA expression profiling of mitochondrial subunits in subjects with Parkinson\u2019s disease. Arch Med Sci [Internet]. 2021, Mar, 28;131629:0, 2.html. https:\/\/www.archivesofmedicalscience.com\/mRNA-expression-profiling-of-mitochondrial-subunits-in-subjects-with-Parkinson-s. 2025 Sep 11];.","DOI":"10.5114\/aoms\/131629"},{"key":"8102_CR133","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ebiom.2018.05.007","volume":"31","author":"S Ugras","year":"2018","unstructured":"Ugras S, Daniels MJ, Fazelinia H, Gould NS, Yocum AK, Luk KC, et al. Induction of the immunoproteasome subunit Lmp7 Links proteostasis and immunity in \u03b1-synuclein aggregation disorders. EBioMedicine. 2018, May;31:307\u201319. https:\/\/doi.org\/10.1016\/j.ebiom.2018.05.007.","journal-title":"EBioMedicine"},{"issue":"6","key":"8102_CR134","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3233\/RNN-180852","volume":"36","author":"R Qadri","year":"2018","unstructured":"Qadri R, Namdeo M, Behari M, Goyal V, Sharma S, Mukhopadhyay AK. Alterations in mitochondrial membrane potential in peripheral blood mononuclear cells in Parkinson\u2019s disease: potential for a novel biomarker. Restor Neurol Neurosci. 2018, Nov, 27;36(6):719\u201327. https:\/\/doi.org\/10.3233\/RNN-180852.","journal-title":"Restor Neurol Neurosci"},{"issue":"29","key":"8102_CR135","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","volume":"36","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Tsunemi T, Toker NJ, Jeon S, Burbulla LF, et al. Activation of -glucocerebrosidase reduces pathological -synuclein and restores lysosomal function in Parkinson\u2019s patient Midbrain neurons. J Neurosci. 2016, Jul, 20;36(29):7693\u2013706. https:\/\/doi.org\/10.1523\/JNEUROSCI.0628-16.2016.","journal-title":"J Neurosci"},{"issue":"6","key":"8102_CR136","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/mds.26562","volume":"31","author":"T Moors","year":"2016","unstructured":"Moors T, Paciotti S, Chiasserini D, Calabresi P, Parnetti L, Beccari T, et al. Lysosomal dysfunction and \u03b1-synuclein aggregation in Parkinson\u2019s disease: diagnostic Links. Mov Disord. 2016, Jun;31(6):791\u2013801. https:\/\/doi.org\/10.1002\/mds.26562.","journal-title":"Mov Disord"},{"key":"8102_CR137","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fnagi.2020.00097","volume":"12","author":"M Avenali","year":"2020","unstructured":"Avenali M, Blandini F, Cerri S. Glucocerebrosidase defects as a major risk factor for Parkinson\u2019s disease. Front Aging Neurosci. 2020, Apr, 21;12:97. https:\/\/doi.org\/10.3389\/fnagi.2020.00097.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"8102_CR138","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3233\/JPD-202138","volume":"10","author":"ML Erb","year":"2020","unstructured":"Erb ML, Moore DJ. LRRK2 and the endolysosomal system in Parkinson\u2019s disease. J Educ Chang Parkinson\u2019s Disease. 2020, Oct, 27;10(4):1271\u201391. https:\/\/doi.org\/10.3233\/JPD-202138.","journal-title":"J Educ Chang Parkinson\u2019s Disease"},{"issue":"5","key":"8102_CR139","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1042\/BST20120119","volume":"40","author":"N Dzamko","year":"2012","unstructured":"Dzamko N, Halliday GM. An emerging role for LRRK2 in the immune system. Biochem Soc Trans. 2012, Oct, 1;40(5):1134\u201339. https:\/\/doi.org\/10.1042\/BST20120119.","journal-title":"Biochem Soc Trans"},{"issue":"7330","key":"8102_CR140","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature09782","volume":"469","author":"B Levine","year":"2011","unstructured":"Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature. 2011, Jan, 20;469(7330):323\u201335. https:\/\/doi.org\/10.1038\/nature09782.","journal-title":"Nature"},{"issue":"2","key":"8102_CR141","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/BJ20070209","volume":"405","author":"M Jaleel","year":"2007","unstructured":"Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson\u2019s disease mutants affect kinase activity. The Biochemical J. 2007, Jul, 15;405(2):307\u201317. https:\/\/doi.org\/10.1042\/BJ20070209.","journal-title":"The Biochemical J"},{"issue":"51","key":"8102_CR142","doi-asserted-by":"publisher","first-page":"18676","DOI":"10.1073\/pnas.0508052102","volume":"102","author":"WW Smith","year":"2005","unstructured":"Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA. 2005, Dec, 20;102(51):18676\u201381. https:\/\/doi.org\/10.1073\/pnas.0508052102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"8102_CR143","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ng.485","volume":"41","author":"W Satake","year":"2009","unstructured":"Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson\u2019s disease. Nat Genet. 2009, Dec;41(12):1303\u201307. https:\/\/doi.org\/10.1038\/ng.485.","journal-title":"Nat Genet"},{"issue":"12","key":"8102_CR144","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/ng.487","volume":"41","author":"J Sim\u00f3n-S\u00e1nchez","year":"2009","unstructured":"Sim\u00f3n-S\u00e1nchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease. Nat Genet. 2009, Dec;41(12):1308\u201312. https:\/\/doi.org\/10.1038\/ng.487.","journal-title":"Nat Genet"},{"issue":"9","key":"8102_CR145","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.4049\/jimmunol.1000548","volume":"185","author":"A Gardet","year":"2010","unstructured":"Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, et al. LRRK2 is involved in the IFN-\u03b3 response and host response to pathogens. J Immunol. 2010, Nov, 1;185(9):5577\u201385. https:\/\/doi.org\/10.4049\/jimmunol.1000548.","journal-title":"J Immunol"},{"key":"8102_CR146","doi-asserted-by":"publisher","unstructured":"Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, et al. The IkappaB kinase family phosphorylates the Parkinson\u2019s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One. 2012, Jun, 18;7(6):e39132. https:\/\/doi.org\/10.1371\/journal.pone.0039132. Dawson, TM, editor.","DOI":"10.1371\/journal.pone.0039132"},{"key":"8102_CR147","doi-asserted-by":"publisher","unstructured":"Th\u00e9venet J, Pescini Gobert R, Hooft Van Huijsduijnen R, Wiessner C, Sagot YJ. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. Sozzani, S, editor. PLoS One. 2011, Jun, 27;6(6):e21519. https:\/\/doi.org\/10.1371\/journal.pone.0021519.","DOI":"10.1371\/journal.pone.0021519"},{"issue":"5","key":"8102_CR148","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00702-011-0653-2","volume":"118","author":"M Hakimi","year":"2011","unstructured":"Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, et al. Parkinson\u2019s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm. 2011, May;118(5):795\u2013808. https:\/\/doi.org\/10.1007\/s00702-011-0653-2.","journal-title":"J Neural Transm"},{"issue":"11","key":"8102_CR149","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/ni.2113","volume":"12","author":"Z Liu","year":"2011","unstructured":"Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol. 2011, Nov;12(11):1063\u201370. https:\/\/doi.org\/10.1038\/ni.2113.","journal-title":"Nat Immunol"},{"issue":"5","key":"8102_CR150","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","volume":"32","author":"MS Moehle","year":"2012","unstructured":"Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci. 2012, Feb, 1;32(5):1602\u201311. https:\/\/doi.org\/10.1523\/JNEUROSCI.5601-11.2012.","journal-title":"J Neurosci"},{"key":"8102_CR151","doi-asserted-by":"publisher","unstructured":"Leucine-rich repeat kinase 2 (LRRK2). In: Rideout HJ, editor. Cham: Springer International Publishing. [2026 Jan 28]. Adv Neurobiol. 2017;14. Available from: https:\/\/doi.org\/10.1007\/978-3-319-49969-7.","DOI":"10.1007\/978-3-319-49969-7"},{"issue":"3","key":"8102_CR152","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mds.70123","volume":"41","author":"JR Mark","year":"2026","unstructured":"Mark JR, Staley HA, Titus AM, Agin-Liebes J, Garrido A, Hughes L, et al. Parkinson\u2019s-linked LRRK2 and GBA1 mutations modulate the peripheral immune response to Pseudomonas aeruginosa. Mov Disord. 2026 Nov 19;mds.70123.41(3):651\u201366. https:\/\/doi.org\/10.1002\/mds.70123.","journal-title":"Mov Disord"},{"issue":"15","key":"8102_CR153","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1093\/hmg\/ddv157","volume":"24","author":"MS Moehle","year":"2015","unstructured":"Moehle MS, Daher JPL, Hull TD, Boddu R, Abdelmotilib HA, Mobley J, et al. The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Hum Mol Genet. 2015, Aug, 1;24(15):4250\u201367. https:\/\/doi.org\/10.1093\/hmg\/ddv157.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"8102_CR154","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1038\/ncomms9255","volume":"6","author":"I Choi","year":"2015","unstructured":"Choi I, Kim B, Byun JW, Baik SH, Huh YH, Kim JH, et al. LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nat Commun. 2015, Sep, 14;6(1):8255. https:\/\/doi.org\/10.1038\/ncomms9255.","journal-title":"Nat Commun"},{"issue":"1","key":"8102_CR155","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41531-021-00170-1","volume":"7","author":"MK Herrick","year":"2021","unstructured":"Herrick MK, Tansey MG. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson\u2019s disease? Npj Parkinsons Dis. 2021, Mar, 9;7(1):26. https:\/\/doi.org\/10.1038\/s41531-021-00170-1.","journal-title":"Npj Parkinsons Dis"},{"issue":"25","key":"8102_CR156","doi-asserted-by":"publisher","first-page":"9289","DOI":"10.1073\/pnas.1403215111","volume":"111","author":"JPL Daher","year":"2014","unstructured":"Daher JPL, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB. Abrogation of \u03b1-synuclein\u2013mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci USA. 2014, Jun, 24;111(25):9289\u201394. https:\/\/doi.org\/10.1073\/pnas.1403215111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"8102_CR157","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","volume":"78","author":"M Anheim","year":"2012","unstructured":"Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology. 2012, Feb, 7;78(6):417\u201320. https:\/\/doi.org\/10.1212\/WNL.0b013e318245f476.","journal-title":"Neurology"},{"issue":"17","key":"8102_CR158","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009, Oct, 22;361(17):1651\u201361. https:\/\/doi.org\/10.1056\/NEJMoa0901281.","journal-title":"N Engl J Med"},{"issue":"2","key":"8102_CR159","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2013.12.003","volume":"111","author":"EI Ginns","year":"2014","unstructured":"Ginns EI, Mak SKK, Ko N, Karlgren J, Akbarian S, Chou VP, et al. Neuroinflammation and \u03b1-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol Genet Metab. 2014, Feb;111(2):152\u201362. https:\/\/doi.org\/10.1016\/j.ymgme.2013.12.003.","journal-title":"Mol Genet Metab"},{"key":"8102_CR160","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nbd.2018.12.001","volume":"124","author":"L Mus","year":"2019","unstructured":"Mus L, Siani F, Giuliano C, Ghezzi C, Cerri S, Blandini F. Development and biochemical characterization of a mouse model of Parkinson\u2019s disease bearing defective glucocerebrosidase activity. Neurobiol Disease. 2019, Apr;124:289\u201396. https:\/\/doi.org\/10.1016\/j.nbd.2018.12.001.","journal-title":"Neurobiol Disease"},{"issue":"6","key":"8102_CR161","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/ars.2015.6307","volume":"23","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, et al. Sustained systemic glucocerebrosidase inhibition induces brain \u03b1-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid Redox Signal. 2015, Aug, 20;23(6):550\u201364. https:\/\/doi.org\/10.1089\/ars.2015.6307.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"8102_CR162","doi-asserted-by":"publisher","first-page":"15446","DOI":"10.1038\/s41598-018-33921-x","volume":"8","author":"F Atashrazm","year":"2018","unstructured":"Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, et al. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease. Sci Rep. 2018, Oct, 18;8(1):15446. https:\/\/doi.org\/10.1038\/s41598-018-33921-x.","journal-title":"Sci Rep"},{"issue":"1","key":"8102_CR163","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/acel.12409","volume":"15","author":"E Aflaki","year":"2016","unstructured":"Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ, et al. Lysosomal storage and impaired autophagy lead to inflammasome activation in G aucher macrophages. Aging Cell. 2016, Feb;15(1):77\u201388. https:\/\/doi.org\/10.1111\/acel.12409.","journal-title":"Aging Cell"},{"issue":"11","key":"8102_CR164","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3390\/pharmaceutics13111779","volume":"13","author":"SR Archie","year":"2021","unstructured":"Archie SR, Al Shoyaib A, Cucullo L. Blood-brain barrier dysfunction in CNS disorders and putative therapeutic targets: an Overview. Pharmaceutics. 2021, Oct, 26;13(11):1779. https:\/\/doi.org\/10.3390\/pharmaceutics13111779.","journal-title":"Pharmaceutics"},{"key":"8102_CR165","doi-asserted-by":"publisher","first-page":"661838","DOI":"10.3389\/fncel.2021.661838","volume":"15","author":"F Takata","year":"2021","unstructured":"Takata F, Nakagawa S, Matsumoto J, Dohgu S. Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction. Front Cell Neurosci. 2021, Sep, 13;15:661838. https:\/\/doi.org\/10.3389\/fncel.2021.661838.","journal-title":"Front. Cell. Neurosci"},{"issue":"2","key":"8102_CR166","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1124\/pr.117.014647","volume":"70","author":"MA Erickson","year":"2018","unstructured":"Erickson MA, Banks WA. Neuroimmune axes of the blood\u2013brain barriers and blood\u2013brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions. Pharmacol Rev. 2018, Apr;70(2):278\u2013314. https:\/\/doi.org\/10.1124\/pr.117.014647.","journal-title":"Pharmacol Rev"},{"key":"8102_CR167","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-60761-938-3_4","volume-title":"The blood-brain and other neural barriers [internet]","author":"CE Johanson","year":"2011","unstructured":"Johanson CE, Stopa EG, McMillan PN. The blood-cerebrospinal fluid barrier: structure and functional significance. In: Nag S, editor. The blood-brain and other neural barriers [internet]. Totowa, NJ: Humana Press. [cited 2025 Sep 11]. Methods Mol Biol. 2011;686:101\u201331. Available from: https:\/\/doi.org\/10.1007\/978-1-60761-938-3_4."},{"issue":"4","key":"8102_CR168","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1083\/jcb.201412147","volume":"209","author":"S Tietz","year":"2015","unstructured":"Tietz S, Engelhardt B. Brain barriers: crosstalk between complex tight junctions and adherens junctions. J Cell Biol. 2015, May, 25;209(4):493\u2013506. https:\/\/doi.org\/10.1083\/jcb.201412147.","journal-title":"J Cell Biol"},{"issue":"4","key":"8102_CR169","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1152\/physrev.00004.2013","volume":"93","author":"HH Damkier","year":"2013","unstructured":"Damkier HH, Brown PD, Praetorius J. Cerebrospinal fluid secretion by the choroid plexus. Physiol Rev. 2013, Oct;93(4):1847\u201392. https:\/\/doi.org\/10.1152\/physrev.00004.2013.","journal-title":"Physiol Rev"},{"issue":"9","key":"8102_CR170","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","volume":"26","author":"B Engelhardt","year":"2005","unstructured":"Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005, Sep;26(9):485\u201395. https:\/\/doi.org\/10.1016\/j.it.2005.07.004.","journal-title":"Trends Immunol"},{"issue":"6","key":"8102_CR171","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00401-017-1758-y","volume":"134","author":"G Llovera","year":"2017","unstructured":"Llovera G, Benakis C, Enzmann G, Cai R, Arzberger T, Ghasemigharagoz A, et al. The choroid plexus is a key cerebral invasion route for T cells after stroke. Acta Neuropathol (Berl). 2017, Dec;134(6):851\u201368. https:\/\/doi.org\/10.1007\/s00401-017-1758-y.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"2","key":"8102_CR172","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/glia.24109","volume":"70","author":"G Lan","year":"2022","unstructured":"Lan G, Wang P, Chan RB, Liu Z, Yu Z, Liu X, et al. Astrocytic VEGFA: an essential mediator in blood\u2013brain-barrier disruption in Parkinson\u2019s disease. Glia. 2022, Feb;70(2):337\u201353. https:\/\/doi.org\/10.1002\/glia.24109.","journal-title":"Glia"},{"issue":"6","key":"8102_CR173","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s12640-021-00414-1","volume":"39","author":"W Li","year":"2021","unstructured":"Li W, Yuan W, Zhang D, Cai S, Luo J, Zeng K. LCZ696 possesses a protective effect against homocysteine (Hcy)-induced impairment of blood\u2013brain barrier (BBB) integrity by increasing Occludin, mediated by the inhibition of egr-1. Neurotox Res. 2021, Dec;39(6):1981\u201390. https:\/\/doi.org\/10.1007\/s12640-021-00414-1.","journal-title":"Neurotox Res"},{"issue":"12","key":"8102_CR174","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nm.3407","volume":"19","author":"B Obermeier","year":"2013","unstructured":"Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013, Dec;19(12):1584\u201396. https:\/\/doi.org\/10.1038\/nm.3407.","journal-title":"Nat Med"},{"issue":"1","key":"8102_CR175","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-019-0147-y","volume":"8","author":"W Zou","year":"2019","unstructured":"Zou W, Pu T, Feng W, Lu M, Zheng Y, Du R, et al. Blocking meningeal lymphatic drainage aggravates Parkinson\u2019s disease-like pathology in mice overexpressing mutated \u03b1-synuclein. Transl Neurodegener. 2019, Dec;8(1):7. https:\/\/doi.org\/10.1186\/s40035-019-0147-y.","journal-title":"Transl Neurodegener"},{"issue":"3","key":"8102_CR176","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41591-020-01198-1","volume":"27","author":"XB Ding","year":"2021","unstructured":"Ding XB, Wang X XX, Xia DH, Liu H, Tian HY, Fu Y, et al. Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson\u2019s disease. Nat Med. 2021, Mar;27(3):411\u201318. https:\/\/doi.org\/10.1038\/s41591-020-01198-1.","journal-title":"Nat Med"},{"issue":"4","key":"8102_CR177","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/j.1471-4159.2008.05697.x","volume":"107","author":"X Chen","year":"2008","unstructured":"Chen X, Lan X, Roche I, Liu R, Geiger JD. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J Neurochem. 2008, Nov;107(4):1147\u201357. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05697.x.","journal-title":"J Neurochem"},{"key":"8102_CR178","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3389\/fphar.2018.01444","volume":"9","author":"JH Choi","year":"2018","unstructured":"Choi JH, Jang M, Lee JI, Chung WS, Cho IH. Neuroprotective effects of a traditional multi-herbal Medicine kyung-ok-Ko in an animal model of Parkinson\u2019s disease: inhibition of MAPKs and NF-\u03baB pathways and activation of Keap1-Nrf2 pathway. Front Pharmacol. 2018, Dec, 13;9:1444. https:\/\/doi.org\/10.3389\/fphar.2018.01444.","journal-title":"Front Pharmacol"},{"key":"8102_CR179","doi-asserted-by":"publisher","unstructured":"Chung YC, Shin WH, Baek JY, Cho EJ, Baik HH, Kim SR, et al. CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson\u2019s disease. Exp Mol Med. 2016, Jan, 22;48(1):e205\u2013205. https:\/\/doi.org\/10.1038\/emm.2015.100.","DOI":"10.1038\/emm.2015.100"},{"key":"8102_CR180","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jns.2017.08.3235","volume":"381","author":"J Liu","year":"2017","unstructured":"Liu J, Wang F, Liu S, Du J, Hu X, Xiong J, et al. Sodium butyrate exerts protective effect against Parkinson\u2019s disease in mice via stimulation of glucagon like peptide-1. J Neurological Sci. 2017, Oct;381:176\u201381. https:\/\/doi.org\/10.1016\/j.jns.2017.08.3235.","journal-title":"J Neurological Sci"},{"issue":"1","key":"8102_CR181","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41531-023-00449-5","volume":"9","author":"Y Qu","year":"2023","unstructured":"Qu Y, Li J, Qin Q, Wang D, Zhao J, An K, et al. A systematic review and meta-analysis of inflammatory biomarkers in Parkinson\u2019s disease. Npj Parkinsons Dis. 2023, Feb, 4;9(1):18. https:\/\/doi.org\/10.1038\/s41531-023-00449-5.","journal-title":"Npj Parkinsons Dis"},{"key":"8102_CR182","doi-asserted-by":"publisher","unstructured":"Barcia C, Ros CM, Annese V, G\u00f3mez A, Ros-Bernal F, Aguado-Llera D, et al. IFN-\u03b3 signaling, with the synergistic contribution of TNF-\u03b1, mediates cell specific microglial and astroglial activation in experimental models of Parkinson\u2019s disease. Cell Death Dis. 2011, Apr, 7;2(4):e142\u2013142. https:\/\/doi.org\/10.1038\/cddis.2011.17.","DOI":"10.1038\/cddis.2011.17"},{"issue":"2","key":"8102_CR183","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/01616412.2015.1133026","volume":"38","author":"V Gupta","year":"2016","unstructured":"Gupta V, Garg RK, Khattri S. Levels of IL-8 and TNF-\u03b1 decrease in Parkinson\u2019s disease. Neurol Res. 2016, Feb;38(2):98\u2013102. https:\/\/doi.org\/10.1080\/01616412.2015.1133026.","journal-title":"Neurol Res"},{"key":"8102_CR184","doi-asserted-by":"crossref","unstructured":"Leal MC, Casabona JC, Puntel M, Pitossi FJ. Interleukin-1\u03b2 and tumor necrosis factor-\u03b1: reliable targets for protective therapies in Parkinson\u2019s disease? Front Cell Neurosci [Internet]. 2013. http:\/\/journal.frontiersin.org\/article\/10.3389\/fncel.2013.00053\/abstract. 2025 Apr 28];.","DOI":"10.3389\/fncel.2013.00053"},{"issue":"1","key":"8102_CR185","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/ijms24010264","volume":"24","author":"G Xiromerisiou","year":"2022","unstructured":"Xiromerisiou G, Marogianni C, Lampropoulos IC, Dardiotis E, Speletas M, Ntavaroukas P, et al. Peripheral inflammatory markers TNF-\u03b1 and CCL2 revisited: association with Parkinson\u2019s disease severity. IJMS. 2022, Dec, 23;24(1):264. https:\/\/doi.org\/10.3390\/ijms24010264.","journal-title":"IJMS"},{"key":"8102_CR186","doi-asserted-by":"publisher","first-page":"106693","DOI":"10.1016\/j.nbd.2024.106693","volume":"201","author":"B Chen","year":"2024","unstructured":"Chen B, Zhou H, Liu X, Yang W, Luo Y, Zhu S, et al. Correlations of gray matter volume with peripheral cytokines in Parkinson\u2019s disease. Neurobiol Disease. 2024, Oct, 15;201:106693. https:\/\/doi.org\/10.1016\/j.nbd.2024.106693.","journal-title":"Neurobiol Disease"},{"key":"8102_CR187","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/j.bbih.2022.100442","volume":"21","author":"K Diaz","year":"2022","unstructured":"Diaz K, Kohut ML, Russell DW, Stegem\u00f6ller EL. Peripheral inflammatory cytokines and motor symptoms in persons with Parkinson\u2019s disease. Brain, Behav, Immun - Health. 2022, May;21:100442. https:\/\/doi.org\/10.1016\/j.bbih.2022.100442.","journal-title":"Brain, Behav, Immun - Health"},{"key":"8102_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/898192","volume":"2015","author":"M Dufek","year":"2015","unstructured":"Dufek M, Rektorova I, Thon V, Lokaj J, Rektor I. Interleukin-6 may contribute to mortality in Parkinson\u2019s disease patients: a 4-year prospective study. Parkinsons Dis. 2015;2015:1\u20135. https:\/\/doi.org\/10.1155\/2015\/898192.","journal-title":"Parkinsons Dis"},{"issue":"4","key":"8102_CR189","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? The Lancet Neurol. 2009, Apr;8(4):382\u201397. https:\/\/doi.org\/10.1016\/S1474-4422(09)70062-6.","journal-title":"The Lancet Neurol"},{"issue":"8","key":"8102_CR190","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"I Peter","year":"2018","unstructured":"Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, et al. Anti\u2013tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 2018, Aug, 1;75(8):939. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0605.","journal-title":"JAMA Neurol"},{"key":"8102_CR191","doi-asserted-by":"publisher","first-page":"1255533","DOI":"10.3389\/fimmu.2023.1255533","volume":"14","author":"E Grebenciucova","year":"2023","unstructured":"Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front. Immunol. 2023, Sep, 28;14:1255533. https:\/\/doi.org\/10.3389\/fimmu.2023.1255533.","journal-title":"Front. Immunol"},{"issue":"8","key":"8102_CR192","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s11064-009-9921-z","volume":"34","author":"KW Hofmann","year":"2009","unstructured":"Hofmann KW, Schuh AFS, Saute J, Townsend R, Fricke D, Leke R, et al. Interleukin-6 serum levels in patients with Parkinson\u2019s disease. Neurochem Res. 2009, Aug;34(8):1401\u201304. https:\/\/doi.org\/10.1007\/s11064-009-9921-z.","journal-title":"Neurochem Res"},{"issue":"3","key":"8102_CR193","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.cyto.2012.07.030","volume":"60","author":"D Koziorowski","year":"2012","unstructured":"Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson\u2019s disease patients. Cytokine. 2012, Dec;60(3):762\u201366. https:\/\/doi.org\/10.1016\/j.cyto.2012.07.030.","journal-title":"Cytokine"},{"issue":"3","key":"8102_CR194","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pneurobio.2009.08.001","volume":"89","author":"CM Long-Smith","year":"2009","unstructured":"Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson\u2019s disease. Prog Neurobiol. 2009, Nov;89(3):277\u201387. https:\/\/doi.org\/10.1016\/j.pneurobio.2009.08.001.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"8102_CR195","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-5-8","volume":"5","author":"JB Koprich","year":"2008","unstructured":"Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1\u03b2 increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson\u2019s disease. J Neuroinflammation. 2008, Dec;5(1):8. https:\/\/doi.org\/10.1186\/1742-2094-5-8.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"8102_CR196","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neulet.2006.12.003","volume":"414","author":"M Mogi","year":"2007","unstructured":"Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferon-\u03b3, and NF-\u03baB levels are elevated in the parkinsonian brain. Neurosci Lett. 2007, Feb;414(1):94\u201397. https:\/\/doi.org\/10.1016\/j.neulet.2006.12.003.","journal-title":"Neurosci Lett"},{"issue":"2","key":"8102_CR197","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.humimm.2022.11.001","volume":"84","author":"S Moradi","year":"2023","unstructured":"Moradi S, Zamani A, Mazdeh M, Ramezani M, Komaki A, Talebi-Ghane E, et al. An inclusive study on cytokine gene expression in Parkinson\u2019s disease: advanced analysis using Bayesian regression model. Hum Immunol. 2023, Feb;84(2):123\u201329. https:\/\/doi.org\/10.1016\/j.humimm.2022.11.001.","journal-title":"Hum Immunol"},{"issue":"12","key":"8102_CR198","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1523\/JNEUROSCI.5321-06.2007","volume":"27","author":"MP Mount","year":"2007","unstructured":"Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, et al. Involvement of interferon-\u03b3 in microglial-mediated loss of dopaminergic neurons. J Neurosci. 2007, Mar, 21;27(12):3328\u201337. https:\/\/doi.org\/10.1523\/JNEUROSCI.5321-06.2007.","journal-title":"J Neurosci"},{"issue":"8","key":"8102_CR199","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.parkreldis.2005.07.005","volume":"11","author":"Y Baba","year":"2005","unstructured":"Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005, Dec;11(8):493\u201398. https:\/\/doi.org\/10.1016\/j.parkreldis.2005.07.005.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"8102_CR200","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3390\/ijms23084148","volume":"23","author":"TW Liu","year":"2022","unstructured":"Liu TW, Chen CM, Chang KH. Biomarker of neuroinflammation in Parkinson\u2019s disease. IJMS. 2022, Apr, 8;23(8):4148. https:\/\/doi.org\/10.3390\/ijms23084148.","journal-title":"IJMS"},{"key":"8102_CR201","doi-asserted-by":"crossref","unstructured":"McLarnon JG. Chemokine Interleukin-8 (IL-8) in Alzheimer\u2019s and Other Neurodegenerative Diseases. J Alzheimers Dis Parkinsonism [Internet]. 2016;6(5). Available from: https:\/\/www.omicsonline.org\/open-access\/chemokine-interleukin8-il8-in-alzheimers-and-otherneurodegenerative-diseases-2161-0460-1000273.php?aid=81180. 2025 Apr 28.","DOI":"10.4172\/2161-0460.1000273"},{"issue":"4","key":"8102_CR202","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10517-020-04723-x","volume":"168","author":"IV Miliukhina","year":"2020","unstructured":"Miliukhina IV, Usenko TS, Senkevich KA, Nikolaev MA, Timofeeva AA, Agapova EA, et al. Plasma cytokines profile in patients with Parkinson\u2019s disease associated with mutations in GBA gene. Bull Exp Biol Med. 2020, Feb;168(4):423\u201326. https:\/\/doi.org\/10.1007\/s10517-020-04723-x.","journal-title":"Bull Exp Biol Med"},{"issue":"1","key":"8102_CR203","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41531-019-0086-4","volume":"5","author":"D Ahmadi Rastegar","year":"2019","unstructured":"Ahmadi Rastegar D, Ho N, Halliday GM, Dzamko N. Parkinson\u2019s progression prediction using machine learning and serum cytokines. Npj Parkinsons Dis. 2019;5(1):14. https:\/\/doi.org\/10.1038\/s41531-019-0086-4.","journal-title":"Npj Parkinsons Dis"},{"key":"8102_CR204","doi-asserted-by":"publisher","first-page":"114926","DOI":"10.1016\/j.expneurol.2024.114926","volume":"381","author":"K Bernard","year":"2024","unstructured":"Bernard K, Mota JA, Wene P, Corenblum MJ, Saez JL, Bartlett MJ, et al. The angiotensin (1\u20137) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson\u2019s disease through modulation of neuroinflammation. Exp Neurol. 2024, Nov;381:114926. https:\/\/doi.org\/10.1016\/j.expneurol.2024.114926.","journal-title":"Exp Neurol"},{"key":"8102_CR205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/208408","volume":"2014","author":"P Tang","year":"2014","unstructured":"Tang P, Chong L, Li X, Liu Y, Liu P, Hou C, et al. Correlation between serum RANTES levels and the severity of Parkinson\u2019s disease. Oxidative Med Cellular Longevity. 2014;2014:1\u20134. https:\/\/doi.org\/10.1155\/2014\/208408.","journal-title":"Oxidative Med Cellular Longevity"},{"key":"8102_CR206","doi-asserted-by":"publisher","first-page":"104575","DOI":"10.1016\/j.nbd.2019.104575","volume":"132","author":"D Dutta","year":"2019","unstructured":"Dutta D, Kundu M, Mondal S, Roy A, Ruehl S, Hall DA, et al. RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson\u2019s disease. Neurobiol Disease. 2019, Dec;132:104575. https:\/\/doi.org\/10.1016\/j.nbd.2019.104575.","journal-title":"Neurobiol Disease"},{"issue":"4","key":"8102_CR207","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1044-7431(03)00081-2","volume":"23","author":"A Sanchezcapelo","year":"2003","unstructured":"Sanchezcapelo A. Transforming growth factor $beta;1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice. Mol Cell Neurosci. 2003, Aug;23(4):614\u201325. https:\/\/doi.org\/10.1016\/S1044-7431(03)00081-2.","journal-title":"Mol Cell Neurosci"},{"issue":"2","key":"8102_CR208","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/exnr.1996.0200","volume":"142","author":"MP Vawter","year":"1996","unstructured":"Vawter MP, Dillon-Carter O, Tourtellotte WW, Carvey P, Freed WJ. TGF\u03b21 and TGF\u03b22 concentrations are elevated in Parkinson\u2019s disease in ventricular cerebrospinal fluid. Exp Neurol. 1996, Dec;142(2):313\u201322. https:\/\/doi.org\/10.1006\/exnr.1996.0200.","journal-title":"Exp Neurol"},{"issue":"1","key":"8102_CR209","doi-asserted-by":"publisher","first-page":"19021","DOI":"10.1038\/srep19021","volume":"6","author":"Z Liu","year":"2016","unstructured":"Liu Z, Guo J, Wang Y, Li K, Kang J, Wei Y, et al. Lack of association between IL-10 and IL-18 gene promoter polymorphisms and Parkinson\u2019s disease with cognitive impairment in a Chinese population. Sci Rep. 2016, Feb, 2;6(1):19021. https:\/\/doi.org\/10.1038\/srep19021.","journal-title":"Sci Rep"},{"issue":"2","key":"8102_CR210","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.intimp.2015.10.032","volume":"29","author":"T-T Zhou","year":"2015","unstructured":"Zhou T-T, Zu G, Wang X, Zhang X-G, Li S, Liang Z-H, et al. Immunomodulatory and neuroprotective effects of ginsenoside Rg1 in the MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) -induced mouse model of Parkinson\u2019s disease. Int Immunopharmacol. 2015, Dec;29(2):334\u201343. https:\/\/doi.org\/10.1016\/j.intimp.2015.10.032.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"8102_CR211","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/brainsci6020018","volume":"6","author":"S Mori","year":"2016","unstructured":"Mori S, Maher P, Conti B. Neuroimmunology of the interleukins 13 and 4. Brain Sci. 2016, Jun, 13;6(2):18. https:\/\/doi.org\/10.3390\/brainsci6020018.","journal-title":"Brain Sci"},{"issue":"6","key":"8102_CR212","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.neurobiolaging.2006.04.011","volume":"28","author":"T Arimoto","year":"2007","unstructured":"Arimoto T, Choi DY, Lu X, Liu M, Nguyen XV XV, Zheng N, et al. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging. 2007, Jun;28(6):894\u2013906. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2006.04.011.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"8102_CR213","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1124\/jpet.106.106351","volume":"319","author":"L Qian","year":"2006","unstructured":"Qian L, Block ML, Wei SJ, Lin C-F, Reece J, Pang H, et al. Interleukin-10 protects Lipopolysaccharide-induced neurotoxicity in primary Midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther. 2006, Oct;319(1):44\u201352. https:\/\/doi.org\/10.1124\/jpet.106.106351.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"8102_CR214","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neulet.2012.02.033","volume":"513","author":"D Li","year":"2012","unstructured":"Li D, He Q, Li R, Xu X, Chen B, Xie A. Interleukin-10 promoter polymorphisms in Chinese patients with Parkinson\u2019s disease. Neurosci Lett. 2012, Apr, 4;513(2):183\u201386. https:\/\/doi.org\/10.1016\/j.neulet.2012.02.033.","journal-title":"Neurosci Lett"},{"issue":"6","key":"8102_CR215","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0033-3182(10)70739-8","volume":"51","author":"M Menza","year":"2010","unstructured":"Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson\u2019s disease. Psychosomatics. 2010;51(6):474\u201379. https:\/\/doi.org\/10.1016\/S0033-3182(10)70739-8.","journal-title":"Psychosomatics"},{"issue":"2","key":"8102_CR216","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neulet.2008.06.040","volume":"441","author":"B Brodacki","year":"2008","unstructured":"Brodacki B, Staszewski J, Toczy\u0142owska B, Koz\u0142owska E, Drela N, Chalimoniuk M, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF\u03b1, and INF\u03b3 concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett. 2008, Aug, 22;441(2):158\u201362. https:\/\/doi.org\/10.1016\/j.neulet.2008.06.040.","journal-title":"Neurosci Lett"},{"issue":"5","key":"8102_CR217","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1600-0404.2008.01103.x","volume":"119","author":"M Rentzos","year":"2009","unstructured":"Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, et al. Circulating interleukin-10 and interleukin-12 in Parkinson\u2019s disease. Acta Neurologica Scandinavica. 2009, May;119(5):332\u201337. https:\/\/doi.org\/10.1111\/j.1600-0404.2008.01103.x.","journal-title":"Acta Neurologica Scandinavica"},{"key":"8102_CR218","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.bbi.2020.04.007","volume":"88","author":"CA Aguirre","year":"2020","unstructured":"Aguirre CA, Concetta Morale M, Peng Q, Sanchez-Alavez M, Cintr\u00f3n-Col\u00f3n R, Feng K, et al. Two single nucleotide polymorphisms in IL13 and IL13RA1 from individuals with idiopathic Parkinson\u2019s disease increase cellular susceptibility to oxidative stress. Brain Behav Immun. 2020, Aug;88:920\u201324. https:\/\/doi.org\/10.1016\/j.bbi.2020.04.007.","journal-title":"Brain Behav Immun"},{"issue":"2","key":"8102_CR219","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.expneurol.2004.05.041","volume":"189","author":"R Betarbet","year":"2004","unstructured":"Betarbet R, Greenamyre J. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp Neurol. 2004, Oct;189(2):393\u2013403. https:\/\/doi.org\/10.1016\/j.expneurol.2004.05.041.","journal-title":"Exp Neurol"},{"key":"8102_CR220","doi-asserted-by":"publisher","first-page":"136768","DOI":"10.1016\/j.neulet.2022.136768","volume":"786","author":"A Roy","year":"2022","unstructured":"Roy A, Banerjee R, Choudhury S, Chatterjee K, Mondal B, Dey S, et al. Novel inflammasome and oxidative modulators in Parkinson\u2019s disease: a prospective study. Neurosci Lett. 2022, Aug;786:136768. https:\/\/doi.org\/10.1016\/j.neulet.2022.136768.","journal-title":"Neurosci Lett"},{"issue":"Pt A","key":"8102_CR221","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neuropharm.2014.10.020","volume":"96","author":"AJ Kwilasz","year":"2015","unstructured":"Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology. 2015, Sep;96(Pt A):55\u201369. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.10.020.","journal-title":"Neuropharmacology"},{"key":"8102_CR222","doi-asserted-by":"publisher","unstructured":"Voet S, Srinivasan S, Lamkanfi M, Van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med. 2019, Jun;11(6):e10248. https:\/\/doi.org\/10.15252\/emmm.201810248.","DOI":"10.15252\/emmm.201810248"},{"issue":"5","key":"8102_CR223","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","volume":"157","author":"M Lamkanfi","year":"2014","unstructured":"Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014, May;157(5):1013\u201322. https:\/\/doi.org\/10.1016\/j.cell.2014.04.007.","journal-title":"Cell"},{"issue":"7","key":"8102_CR224","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016, Jul;16(7):407\u201320. https:\/\/doi.org\/10.1038\/nri.2016.58.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"8102_CR225","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","volume":"13","author":"E Latz","year":"2013","unstructured":"Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013, Jun;13(6):397\u2013411. https:\/\/doi.org\/10.1038\/nri3452.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"8102_CR226","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.4049\/jimmunol.1402658","volume":"194","author":"MA Katsnelson","year":"2015","unstructured":"Katsnelson MA, Rucker LG, Russo HM, Dubyak GR. K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol. 2015, Apr, 15;194(8):3937\u201352. https:\/\/doi.org\/10.4049\/jimmunol.1402658.","journal-title":"J Immunol"},{"issue":"6","key":"8102_CR227","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/ana.24173","volume":"75","author":"J Li","year":"2014","unstructured":"Li J, Yan F, Chen G. Reactive oxygen species and NLRP3 inflammasome activation. Ann Neurol. 2014, Jun;75(6):972\u2013972. https:\/\/doi.org\/10.1002\/ana.24173.","journal-title":"Ann Neurol"},{"issue":"13","key":"8102_CR228","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/ijms20133328","volume":"20","author":"N Kelley","year":"2019","unstructured":"Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an Overview of mechanisms of activation and regulation. IJMS. 2019, Jul, 6;20(13):3328. https:\/\/doi.org\/10.3390\/ijms20133328.","journal-title":"IJMS"},{"issue":"11","key":"8102_CR229","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/jnen\/nly090","volume":"77","author":"F Li","year":"2018","unstructured":"Li F, Ayaki T, Maki T, Sawamoto N, Takahashi R. NLRP3 inflammasome-related proteins are upregulated in the putamen of patients with multiple system atrophy. J Neuropathol Exp Neurol. 2018, Nov, 1;77(11):1055\u201365. https:\/\/doi.org\/10.1093\/jnen\/nly090.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"8102_CR230","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12974-019-1670-6","volume":"17","author":"Z Fan","year":"2020","unstructured":"Fan Z, Pan YT, Zhang ZY, Yang H, Yu SY, Zheng Y, et al. Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson\u2019s disease. J Neuroinflammation. 2020, Jan, 8;17(1):11. https:\/\/doi.org\/10.1186\/s12974-019-1670-6.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"8102_CR231","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41531-020-00147-6","volume":"7","author":"FL Anderson","year":"2021","unstructured":"Anderson FL, Von Herrmann KM, Andrew AS, Kuras YI, Young AL, Scherzer CR, et al. Plasma-borne indicators of inflammasome activity in Parkinson\u2019s disease patients. Npj Parkinsons Dis. 2021, Jan, 4;7(1):2. https:\/\/doi.org\/10.1038\/s41531-020-00147-6.","journal-title":"Npj Parkinsons Dis"},{"issue":"6","key":"8102_CR232","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3171\/2012.9.JNS12815","volume":"117","author":"S Adamczak","year":"2012","unstructured":"Adamczak S, Dale G, De Rivero Vaccari JP, Bullock MR, Dietrich WD, Keane RW. Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article. JNS. 2012, Dec;117(6):1119\u201325. https:\/\/doi.org\/10.3171\/2012.9.JNS12815.","journal-title":"JNS"},{"key":"8102_CR233","doi-asserted-by":"publisher","unstructured":"Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, et al. Triggering of inflammasome by aggregated \u03b1\u2013synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8(1):e55375. https:\/\/doi.org\/10.1371\/journal.pone.0055375.","DOI":"10.1371\/journal.pone.0055375"},{"issue":"1","key":"8102_CR234","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1196\/annals.1299.124","volume":"1010","author":"C Colombo","year":"2003","unstructured":"Colombo C, Cosentino M, Marino F, Rasini E, Ossola M, Blandini F, et al. Dopaminergic modulation of apoptosis in human peripheral blood mononuclear cells: possible relevance for Parkinson\u2019s disease. Ann New Y Acad Sci. 2003, Dec;1010(1):679\u201382. https:\/\/doi.org\/10.1196\/annals.1299.124.","journal-title":"Ann New Y Acad Sci"},{"issue":"1\u20132","key":"8102_CR235","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","volume":"160","author":"Y Yan","year":"2015","unstructured":"Yan Y, Jiang W, Liu L, Wang X, Ding C, Tian Z, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell. 2015, Jan;160(1\u20132):62\u201373. https:\/\/doi.org\/10.1016\/j.cell.2014.11.047.","journal-title":"Cell"},{"issue":"2","key":"8102_CR236","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41418-018-0124-5","volume":"26","author":"E Lee","year":"2019","unstructured":"Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019, Feb;26(2):213\u201328. https:\/\/doi.org\/10.1038\/s41418-018-0124-5.","journal-title":"Cell Death Differ"},{"issue":"1","key":"8102_CR237","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12974-018-1236-z","volume":"15","author":"C Qiao","year":"2018","unstructured":"Qiao C, Zhang Q, Jiang Q, Zhang T, Chen M, Fan Y, et al. Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP\/p mouse model of Parkinson\u2019s disease. J Neuroinflammation. 2018, Jul, 2;15(1):193. https:\/\/doi.org\/10.1186\/s12974-018-1236-z.","journal-title":"J Neuroinflammation"},{"key":"8102_CR238","doi-asserted-by":"publisher","unstructured":"Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, et al. Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018, Oct, 31;10(465):eaah 4066. https:\/\/doi.org\/10.1126\/scitranslmed.aah4066.","DOI":"10.1126\/scitranslmed.aah4066"},{"key":"8102_CR239","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.freeradbiomed.2019.01.003","volume":"134","author":"LL Xu","year":"2019","unstructured":"Xu LL, Wu YF, Yan F, Li CC, Dai Z, You QD, et al. 5-(3,4-difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson\u2019s disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress. Free Radic Biol Med. 2019, Apr;134:288\u2013303. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.01.003.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"8102_CR240","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12974-023-02830-w","volume":"20","author":"J Amo-Aparicio","year":"2023","unstructured":"Amo-Aparicio J, Daly J, H\u00f8jen JF, Dinarello CA. Pharmacologic inhibition of NLRP3 reduces the levels of \u03b1-synuclein and protects dopaminergic neurons in a model of Parkinson\u2019s disease. J Neuroinflammation. 2023, Jun, 22;20(1):147. https:\/\/doi.org\/10.1186\/s12974-023-02830-w.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"8102_CR241","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jnc.14104","volume":"142","author":"JF Havelund","year":"2017","unstructured":"Havelund JF, Andersen AD, Binzer M, Blaabjerg M, Heegaard NHH, Stenager E, et al. Changes in kynurenine pathway metabolism in Parkinson patients with L- DOPA -induced dyskinesia. J Neurochem. 2017, Sep;142(5):756\u201366. https:\/\/doi.org\/10.1111\/jnc.14104.","journal-title":"J Neurochem"},{"issue":"11","key":"8102_CR242","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/mds.28202","volume":"35","author":"PL Heilman","year":"2020","unstructured":"Heilman PL, Wang EW, Lewis MM, Krzyzanowski S, Capan CD, Burmeister AR, et al. Tryptophan metabolites are associated with symptoms and Nigral pathology in Parkinson\u2019s disease. Mov Disord. 2020, Nov;35(11):2028\u201337. https:\/\/doi.org\/10.1002\/mds.28202.","journal-title":"Mov Disord"},{"issue":"1","key":"8102_CR243","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41531-024-00785-0","volume":"10","author":"S Shima","year":"2024","unstructured":"Shima S, Mizutani Y, Yoshimoto J, Maeda Y, Ohdake R, Nagao R, et al. Uric acid and alterations of purine recycling disorders in Parkinson\u2019s disease: a cross-sectional study. Npj Parkinsons Dis. 2024, Sep, 9;10(1):170. https:\/\/doi.org\/10.1038\/s41531-024-00785-0.","journal-title":"Npj Parkinsons Dis"},{"issue":"1","key":"8102_CR244","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41531-024-00671-9","volume":"10","author":"EG De Lope","year":"2024","unstructured":"De Lope EG, Loo RTJ, Rauschenberger A, Ali M, Pavelka L, Marques TM, et al. Comprehensive blood metabolomics profiling of Parkinson\u2019s disease reveals coordinated alterations in xanthine metabolism. Npj Park Dis. 2024, Mar, 19;10(1):68.","journal-title":"Npj Park Dis"},{"issue":"4","key":"8102_CR245","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1007\/s12035-022-03179-6","volume":"60","author":"Y Jin","year":"2023","unstructured":"Jin Y, Wu R, Li L, Shen L, Gu Y, Sun C. Exosomes from inflamed macrophages promote the progression of Parkinson\u2019s disease by inducing neuroinflammation. Mol Neurobiol. 2023, Apr;60(4):1914\u201328. https:\/\/doi.org\/10.1007\/s12035-022-03179-6.","journal-title":"Mol Neurobiol"},{"key":"8102_CR246","doi-asserted-by":"publisher","unstructured":"Saedi S, Hemmati-Dinarvand M, Barmaki H, Mokhtari Z, Musavi H, Valilo M, et al. The serum lipid profile of Parkinson\u2019s disease patients: a study from the Northwest of Iran. Casp J Intern Med [Internet]. 2021, Mar;12(2). Available from: https:\/\/doi.org\/10.22088\/cjim.12.2.155. 2025 Sep 11.","DOI":"10.22088\/cjim.12.2.155"},{"issue":"4","key":"8102_CR247","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3233\/JPD-223179","volume":"12","author":"SJ Chen","year":"2022","unstructured":"Chen SJ, Chen CC, Liao HY, Wu YW, Liou JM, Wu MS, et al. Alteration of gut microbial metabolites in the systemic circulation of patients with Parkinson\u2019s disease. JPD. 2022, May, 24;12(4):1219\u201330. https:\/\/doi.org\/10.3233\/JPD-223179.","journal-title":"JPD"},{"issue":"1","key":"8102_CR248","doi-asserted-by":"publisher","first-page":"113132","DOI":"10.1016\/j.yexcr.2022.113132","volume":"417","author":"Q Sun","year":"2022","unstructured":"Sun Q, Zhang Y, Wang S, Yang F, Cai H, Xing Y, et al. LncRNA HOTAIR promotes \u03b1-synuclein aggregation and apoptosis of SH-SY5Y cells by regulating miR-221-3p in Parkinson\u2019s disease. Exp Cell Res. 2022, Aug;417(1):113132. https:\/\/doi.org\/10.1016\/j.yexcr.2022.113132.","journal-title":"Exp Cell Res"},{"key":"8102_CR249","doi-asserted-by":"publisher","unstructured":"Dahabiyeh LA, Nimer RM, Wells JD, Abu-Rish EY, Fiehn O. Diagnosing Parkinson\u2019s disease and monitoring its progression: biomarkers from combined GC-TOF MS and LC-MS\/MS untargeted metabolomics. Heliyon. 2024, May;10(9):e30452. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30452.","DOI":"10.1016\/j.heliyon.2024.e30452"},{"issue":"3","key":"8102_CR250","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/metabo15030208","volume":"15","author":"EA Ostrakhovitch","year":"2025","unstructured":"Ostrakhovitch EA, Ono K, Yamasaki TR. Metabolomics in Parkinson\u2019s disease and correlation with disease state. Metabolites. 2025, Mar, 18;15(3):208. https:\/\/doi.org\/10.3390\/metabo15030208.","journal-title":"Metabolites"},{"issue":"12","key":"8102_CR251","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.3390\/biomedicines10123005","volume":"10","author":"P G\u0105tarek","year":"2022","unstructured":"G\u0105tarek P, Sekulska-Nalewajko J, Bobrowska-Korczaka B, Pawe\u0142czyk M, Jastrz\u0119bski K, G\u0142\u0105bi\u0144ski A, et al. Plasma metabolic disturbances in Parkinson\u2019s disease patients. Biomedicines. 2022, Nov, 22;10(12):3005. https:\/\/doi.org\/10.3390\/biomedicines10123005.","journal-title":"Biomedicines"},{"issue":"1","key":"8102_CR252","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12987-023-00494-5","volume":"20","author":"J Serrano-Mar\u00edn","year":"2023","unstructured":"Serrano-Mar\u00edn J, Marin S, Bernal-Casas D, Lillo A, Gonz\u00e1lez-Sub\u00edas M, Navarro G, et al. A metabolomics study in aqueous humor discloses altered arginine metabolism in Parkinson\u2019s disease. Fluids Barriers CNS. 2023, Dec, 4;20(1):90. https:\/\/doi.org\/10.1186\/s12987-023-00494-5.","journal-title":"Fluids Barriers CNS"},{"issue":"10","key":"8102_CR253","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1093\/brain\/awac176","volume":"145","author":"J Galper","year":"2022","unstructured":"Galper J, Dean NJ, Pickford R, Lewis SJG, Halliday GM, Kim WS, et al. Lipid pathway dysfunction is prevalent in patients with Parkinson\u2019s disease. Brain. 2022, Oct, 21;145(10):3472\u201387. https:\/\/doi.org\/10.1093\/brain\/awac176.","journal-title":"Brain"},{"issue":"1","key":"8102_CR254","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13024-023-00694-5","volume":"18","author":"KC Paul","year":"2023","unstructured":"Paul KC, Zhang K, Walker DI, Sinsheimer J, Yu Y, Kusters C, et al. Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson\u2019s disease. Mol Neurodegener. 2023, Dec, 19;18(1):100. https:\/\/doi.org\/10.1186\/s13024-023-00694-5.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"8102_CR255","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao Y, Li T, Liu Z, Wang X, Xu X, Li S, et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol Neurodegener. 2021, Dec;16(1):4. https:\/\/doi.org\/10.1186\/s13024-021-00425-8.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"8102_CR256","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Th\u00e9ry","year":"2018","unstructured":"Th\u00e9ry C, Witwer KW, Berardi AC, Jovanovic-Talisman T, Jung S, Kalluri R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018, Dec;7(1):1535750.","journal-title":"J Extracell Vesicles"},{"issue":"3","key":"8102_CR257","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.nbd.2007.11.004","volume":"29","author":"ML Bader Lange","year":"2008","unstructured":"Bader Lange ML, Cenini G, Piroddi M, Mohmmad Abdul H, Sultana R, Galli F, et al. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Disease. 2008, Mar;29(3):456\u201364. https:\/\/doi.org\/10.1016\/j.nbd.2007.11.004.","journal-title":"Neurobiol Disease"},{"issue":"1","key":"8102_CR258","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/ATVBAHA.109.200956","volume":"31","author":"O Morel","year":"2011","unstructured":"Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. ATVB. 2011, Jan;31(1):15\u201326. https:\/\/doi.org\/10.1161\/ATVBAHA.109.200956.","journal-title":"ATVB"},{"issue":"3","key":"8102_CR259","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/ijms25031629","volume":"25","author":"FM Filannino","year":"2024","unstructured":"Filannino FM, Panaro MA, Benameur T, Pizzolorusso I, Porro C. Extracellular vesicles in the central nervous system: a novel mechanism of neuronal cell communication. IJMS. 2024, Jan, 28;25(3):1629. https:\/\/doi.org\/10.3390\/ijms25031629.","journal-title":"IJMS"},{"key":"8102_CR260","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.conb.2016.04.016","volume":"39","author":"EM Kr\u00e4mer-Albers","year":"2016","unstructured":"Kr\u00e4mer-Albers EM, Hill AF. Extracellular vesicles: interneural shuttles of complex messages. Curr Opin Neurobiol. 2016, Aug;39:101\u201307. https:\/\/doi.org\/10.1016\/j.conb.2016.04.016.","journal-title":"Curr Opin Neurobiol"},{"issue":"28","key":"8102_CR261","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1007\/s00216-024-05518-z","volume":"416","author":"MD Banadaki","year":"2024","unstructured":"Banadaki MD, Rummel NG, Backus S, Butterfield DA, St Clair DK, Campbell JM, et al. Extraction of redox extracellular vesicles using exclusion-based sample preparation. Anal Bioanal Chem. 2024, Nov;416(28):6317\u201331. https:\/\/doi.org\/10.1007\/s00216-024-05518-z.","journal-title":"Anal Bioanal Chem"},{"issue":"9","key":"8102_CR262","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1091\/mbc.e13-04-0212","volume":"25","author":"RS Flannagan","year":"2014","unstructured":"Flannagan RS, Canton J, Furuya W, Glogauer M, Grinstein S. The phosphatidylserine receptor TIM4 utilizes integrins as coreceptors to effect phagocytosis. MBoC. 2014, May;25(9):1511\u201322. https:\/\/doi.org\/10.1091\/mbc.e13-04-0212.","journal-title":"MBoC"},{"issue":"6","key":"8102_CR263","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bbamem.2016.02.011","volume":"1858","author":"AM Janas","year":"2016","unstructured":"Janas AM, Sapo\u0144 K, Janas T, Stowell MHB, Janas T. Exosomes and other extracellular vesicles in neural cells and neurodegenerative diseases. Biochim Et Biophys Acta (BBA) - Biomembr. 2016, Jun;1858(6):1139\u201351. https:\/\/doi.org\/10.1016\/j.bbamem.2016.02.011.","journal-title":"Biochim Et Biophys Acta (BBA) - Biomembr"},{"key":"8102_CR264","doi-asserted-by":"publisher","unstructured":"Ruzafa D, Hernandez-Gomez YS, Bisello G, Broersen K, Morel B, Conejero-Lara F. The influence of N-terminal acetylation on micelle-induced conformational changes and aggregation of \u03b1-synuclein. Witt, SN, editor. PLoS One. 2017, May, 31;12(5):e0178576. https:\/\/doi.org\/10.1371\/journal.pone.0178576.","DOI":"10.1371\/journal.pone.0178576"},{"issue":"9","key":"8102_CR265","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1073\/pnas.97.9.4897","volume":"97","author":"LC Serpell","year":"2000","unstructured":"Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic \u03b1-synuclein filaments shows amyloid-like cross-\u03b2 conformation. Proc Natl Acad Sci USA. 2000, Apr, 25;97(9):4897\u2013902. https:\/\/doi.org\/10.1073\/pnas.97.9.4897.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"8102_CR266","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1523\/JNEUROSCI.5699-09.2010","volume":"30","author":"E Emmanouilidou","year":"2010","unstructured":"Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell-produced \u03b1-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010, May, 19;30(20):6838\u201351. https:\/\/doi.org\/10.1523\/JNEUROSCI.5699-09.2010.","journal-title":"J Neurosci"},{"issue":"5","key":"8102_CR267","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/brain\/awaa090","volume":"143","author":"M Guo","year":"2020","unstructured":"Guo M, Wang J, Zhao Y, Feng Y, Han S, Dong Q, et al. Microglial exosomes facilitate \u03b1-synuclein transmission in Parkinson\u2019s disease. Brain. 2020, May, 1;143(5):1476\u201397. https:\/\/doi.org\/10.1093\/brain\/awaa090.","journal-title":"Brain"},{"issue":"3","key":"8102_CR268","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/jnc.15288","volume":"157","author":"JR Pinnell","year":"2021","unstructured":"Pinnell JR, Cui M, Tieu K. Exosomes in Parkinson disease. J Neurochem. 2021, May;157(3):413\u201328. https:\/\/doi.org\/10.1111\/jnc.15288.","journal-title":"J Neurochem"},{"key":"8102_CR269","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3389\/fimmu.2019.01069","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou J, Yang R, Zhang Z, Liu Q, Zhang Y, Wang Q, et al. Mitochondrial protein PINK1 positively regulates RLR signaling. Front. Immunol. 2019;10:1069. https:\/\/doi.org\/10.3389\/fimmu.2019.01069.","journal-title":"Front. Immunol"},{"issue":"1","key":"8102_CR270","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-7-42","volume":"7","author":"KM Danzer","year":"2012","unstructured":"Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012, Dec;7(1):42. https:\/\/doi.org\/10.1186\/1750-1326-7-42.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"8102_CR271","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/brain\/awv346","volume":"139","author":"A Stuendl","year":"2016","unstructured":"Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, et al. Induction of \u03b1-synuclein aggregate formation by CSF exosomes from patients with Parkinson\u2019s disease and dementia with Lewy bodies. Brain. 2016, Feb;139(2):481\u201394. https:\/\/doi.org\/10.1093\/brain\/awv346.","journal-title":"Brain"},{"issue":"2","key":"8102_CR272","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ana.26421","volume":"92","author":"Y Huang","year":"2022","unstructured":"Huang Y, Liu Z, Li N, Tian C, Yang H, Huo Y, et al. Parkinson\u2019s disease derived exosomes aggravate neuropathology in SNCA * A53T mice. Ann Neurol. 2022, Aug;92(2):230\u201345. https:\/\/doi.org\/10.1002\/ana.26421.","journal-title":"Ann Neurol"},{"issue":"4","key":"8102_CR273","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3233\/JPD-230390","volume":"14","author":"E Schaeffer","year":"2024","unstructured":"Schaeffer E, Kluge A, Schulte C, Deuschle C, Bunk J, Welzel J, et al. Association of misfolded \u03b1-synuclein derived from neuronal exosomes in blood with Parkinson\u2019s disease diagnosis and duration. J Educ Chang Parkinson\u2019s Disease. 2024, Jun, 4;14(4):667\u201379. https:\/\/doi.org\/10.3233\/JPD-230390.","journal-title":"J Educ Chang Parkinson\u2019s Disease"},{"issue":"1","key":"8102_CR274","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamaneurol.2023.4398","volume":"81","author":"S Yan","year":"2024","unstructured":"Yan S, Jiang C, Janzen A, Barber TR, Seger A, Sommerauer M, et al. Neuronally derived extracellular vesicle \u03b1-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease. JAMA Neurol. 2024, Jan, 1;81(1):59. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4398.","journal-title":"JAMA Neurol"},{"key":"8102_CR275","doi-asserted-by":"publisher","first-page":"578222","DOI":"10.1016\/j.jneuroim.2023.578222","volume":"385","author":"L Wang","year":"2023","unstructured":"Wang L, Yi H, Liang X, Xu F, Li T, Yang X, et al. Plasma TNF-\u03b1 and phosphorylated \u03b1-syn are associated with fatigue in patients with Parkinson\u2019s disease. J Neuroimmunol. 2023, Dec, 15;385:578222. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578222.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"8102_CR276","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s13760-023-02452-2","volume":"124","author":"H Shu","year":"2024","unstructured":"Shu H, Zhang P, Gu L. Alpha-synuclein in peripheral body fluid as a biomarker for Parkinson\u2019s disease. Acta Neurol Belg. 2024, Jun;124(3):831\u201342. https:\/\/doi.org\/10.1007\/s13760-023-02452-2.","journal-title":"Acta Neurol Belg"},{"issue":"9","key":"8102_CR277","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00109-019-01810-z","volume":"97","author":"C Han","year":"2019","unstructured":"Han C, Xiong N, Guo X, Huang J, Ma K, Liu L, et al. Exosomes from patients with Parkinson\u2019s disease are pathological in mice. J Mol Med. 2019, Sep;97(9):1329\u201344. https:\/\/doi.org\/10.1007\/s00109-019-01810-z.","journal-title":"J Mol Med"},{"issue":"1","key":"8102_CR278","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/brain\/awac261","volume":"146","author":"S Herman","year":"2023","unstructured":"Herman S, Djaldetti R, Mollenhauer B, Offen D. CSF-derived extracellular vesicles from patients with Parkinson\u2019s disease induce symptoms and pathology. Brain. 2023, Jan, 5;146(1):209\u201324. https:\/\/doi.org\/10.1093\/brain\/awac261.","journal-title":"Brain"},{"issue":"1","key":"8102_CR279","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40478-017-0445-5","volume":"5","author":"J Ngolab","year":"2017","unstructured":"Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, et al. RETRACTED ARTICLE: brain-derived exosomes from dementia with Lewy bodies propagate \u03b1-synuclein pathology. Acta Neuropathol Commun. 2017, Dec;5(1):46. https:\/\/doi.org\/10.1186\/s40478-017-0445-5.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"8102_CR280","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41419-019-1404-9","volume":"10","author":"Y Xia","year":"2019","unstructured":"Xia Y, Zhang G, Han C, Ma K, Guo X, Wan F, et al. Microglia as modulators of exosomal alpha-synuclein transmission. Cell Death Dis. 2019, Feb, 20;10(3):174. https:\/\/doi.org\/10.1038\/s41419-019-1404-9.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8102_CR281","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","volume":"173","author":"DP Bartel","year":"2018","unstructured":"Bartel DP. Metazoan MicroRNAs. Cell. 2018, Mar;173(1):20\u201351. https:\/\/doi.org\/10.1016\/j.cell.2018.03.006.","journal-title":"Cell"},{"key":"8102_CR282","doi-asserted-by":"publisher","first-page":"146331","DOI":"10.1016\/j.brainres.2019.146331","volume":"1722","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Liu J, Chen L, Jin Y, Zhang G, Lin Z, et al. Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson\u2019s disease. Brain Res. 2019, Nov;1722:146331. https:\/\/doi.org\/10.1016\/j.brainres.2019.146331.","journal-title":"Brain Res"},{"issue":"6","key":"8102_CR283","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.3390\/ijms22062951","volume":"22","author":"F Anastasi","year":"2021","unstructured":"Anastasi F, Masciandaro SM, Carratore RD, Dell\u2019anno MT, Signore G, Falleni A, et al. Proteomics profiling of neuron-derived small extracellular vesicles from human plasma: enabling single-subject analysis. IJMS. 2021, Mar, 14;22(6):2951. https:\/\/doi.org\/10.3390\/ijms22062951.","journal-title":"IJMS"},{"issue":"2","key":"8102_CR284","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12015-020-10050-5","volume":"18","author":"X Xia","year":"2022","unstructured":"Xia X, Wang Y, Zheng JC. The microRNA-17 ~ 92 family as a key regulator of neurogenesis and potential regenerative therapeutics of Neurological disorders. STEM Cell Rev Rep. 2022, Feb;18(2):401\u201311. https:\/\/doi.org\/10.1007\/s12015-020-10050-5.","journal-title":"STEM Cell Rev Rep"},{"key":"8102_CR285","doi-asserted-by":"publisher","first-page":"136414","DOI":"10.1016\/j.neulet.2021.136414","volume":"771","author":"Y Li","year":"2022","unstructured":"Li Y, Li Z, Gu J, Xu X, Chen H, Gui Y. Exosomes isolated during dopaminergic neuron differentiation suppressed neuronal inflammation in a rodent model of Parkinson\u2019s disease. Neurosci Lett. 2022, Feb;771:136414. https:\/\/doi.org\/10.1016\/j.neulet.2021.136414.","journal-title":"Neurosci Lett"},{"issue":"3","key":"8102_CR286","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4062\/biomolther.2022.092","volume":"31","author":"T Huang","year":"2023","unstructured":"Huang T, Zhao D, Lee S, Keum G, Yang HO. Sinapic acid attenuates the neuroinflammatory response by targeting AKT and MAPK in LPS-Activated microglial models. Biomol Ther (Seoul). 2023, May, 1;31(3):276\u201384. https:\/\/doi.org\/10.4062\/biomolther.2022.092.","journal-title":"Biomol Ther (Seoul)"},{"issue":"7","key":"8102_CR287","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","volume":"35","author":"Y Tian","year":"2014","unstructured":"Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014, Feb;35(7):2383\u201390. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.11.083.","journal-title":"Biomaterials"},{"issue":"4","key":"8102_CR288","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3390\/nu13041318","volume":"13","author":"T Benameur","year":"2021","unstructured":"Benameur T, Soleti R, Porro C. The potential neuroprotective role of free and encapsulated quercetin mediated by miRNA against Neurological diseases. Nutrients. 2021, Apr, 16;13(4):1318. https:\/\/doi.org\/10.3390\/nu13041318.","journal-title":"Nutrients"},{"issue":"1","key":"8102_CR289","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/molecules27010236","volume":"27","author":"T Benameur","year":"2021","unstructured":"Benameur T, Giacomucci G, Panaro MA, Ruggiero M, Trotta T, Monda V, et al. New promising therapeutic avenues of curcumin in brain diseases. Molecules. 2021, Dec, 31;27(1):236. https:\/\/doi.org\/10.3390\/molecules27010236.","journal-title":"Molecules"},{"issue":"1","key":"8102_CR290","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41467-018-03733-8","volume":"9","author":"R Kojima","year":"2018","unstructured":"Kojima R, Bojar D, Rizzi G, Hamri GCE, El-Baba MD, Saxena P, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson\u2019s disease treatment. Nat Commun. 2018, Apr, 3;9(1):1305. https:\/\/doi.org\/10.1038\/s41467-018-03733-8.","journal-title":"Nat Commun"},{"key":"8102_CR291","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jconrel.2018.08.035","volume":"287","author":"M Qu","year":"2018","unstructured":"Qu M, Lin Q, Huang L, Fu Y, Wang L, He S, et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson\u2019s disease. J Control Release. 2018, Oct;287:156\u201366. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.035.","journal-title":"J Control Release"},{"issue":"12","key":"8102_CR292","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/mds.25978","volume":"29","author":"JM Cooper","year":"2014","unstructured":"Cooper JM, Wiklander PBO, Nordin JZ, Al-Shawi R, Wood MJ, Vithlani M, et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice: siRNA-exosome decreased alpha-synuclein aggregates. Mov Disord. 2014, Oct;29(12):1476\u201385. https:\/\/doi.org\/10.1002\/mds.25978.","journal-title":"Mov Disord"},{"issue":"9","key":"8102_CR293","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/biom10091320","volume":"10","author":"R Guy","year":"2020","unstructured":"Guy R, Offen D. Promising opportunities for treating neurodegenerative diseases with mesenchymal stem cell-derived exosomes. Biomolecules. 2020, Sep, 15;10(9):1320. https:\/\/doi.org\/10.3390\/biom10091320.","journal-title":"Biomolecules"},{"issue":"1","key":"8102_CR294","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","volume":"8","author":"X Dong-Chen","year":"2023","unstructured":"Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P. Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions. Sig Transduct Target Ther. 2023, Feb, 21;8(1):73. https:\/\/doi.org\/10.1038\/s41392-023-01353-3.","journal-title":"Sig Transduct Target Ther"},{"issue":"5","key":"8102_CR295","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-240272","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update. J Educ Chang Parkinson\u2019s Disease. 2024, Jul, 23;14(5):899\u2013912. https:\/\/doi.org\/10.3233\/JPD-240272.","journal-title":"J Educ Chang Parkinson\u2019s Disease"},{"issue":"13","key":"8102_CR296","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.3390\/ijms26136416","volume":"26","author":"MS Khan","year":"2025","unstructured":"Khan MS, Nasiripour S, Bopassa JC. Parkinson disease signaling pathways, molecular mechanisms, and potential therapeutic strategies: a comprehensive review. IJMS. 2025, Jul, 3;26(13):6416. https:\/\/doi.org\/10.3390\/ijms26136416.","journal-title":"IJMS"},{"issue":"1","key":"8102_CR297","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13024-025-00918-w","volume":"20","author":"D Hu","year":"2025","unstructured":"Hu D, Sun X, Qi X. Disrupting \u03b1-Synuclein\u2013ClpP interaction restores mitochondrial function and attenuates neuropathology in Parkinson\u2019s disease models. Mol Neurodegener. 2025, Dec, 22;20(1):126. https:\/\/doi.org\/10.1186\/s13024-025-00918-w.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"8102_CR298","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.brainres.2006.04.013","volume":"1095","author":"V Di Matteo","year":"2006","unstructured":"Di Matteo V, Pierucci M, Di Giovanni G, Di Santo A, Poggi A, Benigno A, et al. Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res. 2006, Jun;1095(1):167\u201377. https:\/\/doi.org\/10.1016\/j.brainres.2006.04.013.","journal-title":"Brain Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08102-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08102-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08102-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:08:23Z","timestamp":1779926903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08102-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":298,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8102"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08102-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no known competing financial interests or relationships that could influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"713"}}